Publications

@article{pmid37473614b,

title = {Association of electronic nicotine delivery system (ENDS) and cigarette solo and dual use with alcohol-related consequences among US adults},

author = {Brett W Gelino and Derek D Reed and Tory R Spindle and Michael Amlung and Justin C Strickland},

doi = {10.1016/j.addbeh.2023.107806},

issn = {1873-6327},

year  = {2023},

date = {2023-11-01},

journal = {Addict Behav},

volume = {146},

pages = {107806},

abstract = {INTRODUCTION: Research reports a robust association between combustible cigarette use and alcohol use frequency and severity. Extension to the emerging landscape of electronic nicotine delivery system (ENDS) use is needed to inform prevention and treatment strategies.nnMETHOD: We evaluated data from the 2020 National Survey on Drug Use and Health (NSDUH). Respondents included adults reporting cigarettes or ENDS solo or dual use. Multivariable logistic regression models evaluated associations with alcohol use disorder (AUD) and alcohol-related risky behavior (i.e., heavy drinking, binge alcohol use, and driving after drinking) compared to never use controls and respondents with a history, but not current, use of cigarettes or ENDS.nnRESULTS: Multivariable models showed greater odds of AUD for respondents with dual ENDS and cigarette use (AOR = 10.2), ENDS use (AOR = 6.27), cigarette use (AOR = 4.45), and a history, but not ongoing, use (AOR = 2.60) relative to respondents with no use history. Similarly, respondents with dual use (AOR = 3.94), ENDS use (AOR = 2.41), and cigarette use (AOR = 1.71) had greater odds of AUD relative to those with a history of, but not ongoing, use. The association between dual use and AUD was greater for adults ages 21-25 (AOR = 16.2) than for adults over 25 (AOR = 7.82). Cigarette and ENDS solo and dual-use were similarly associated with greater odds of alcohol-related risky behavior relative to control groups.nnCONCLUSION: These findings demonstrate that nicotine use and dual use may be associated with indicators of problematic drinking. These results offer insight into emerging licit polysubstance profiles and call for mechanistic research to inform prevention and intervention efforts.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37473614,

title = {Association of electronic nicotine delivery system (ENDS) and cigarette solo and dual use with alcohol-related consequences among US adults},

author = {Brett W Gelino and Derek D Reed and Tory R Spindle and Michael Amlung and Justin C Strickland},

doi = {10.1016/j.addbeh.2023.107806},

issn = {1873-6327},

year  = {2023},

date = {2023-11-01},

journal = {Addict Behav},

volume = {146},

pages = {107806},

abstract = {INTRODUCTION: Research reports a robust association between combustible cigarette use and alcohol use frequency and severity. Extension to the emerging landscape of electronic nicotine delivery system (ENDS) use is needed to inform prevention and treatment strategies.nnMETHOD: We evaluated data from the 2020 National Survey on Drug Use and Health (NSDUH). Respondents included adults reporting cigarettes or ENDS solo or dual use. Multivariable logistic regression models evaluated associations with alcohol use disorder (AUD) and alcohol-related risky behavior (i.e., heavy drinking, binge alcohol use, and driving after drinking) compared to never use controls and respondents with a history, but not current, use of cigarettes or ENDS.nnRESULTS: Multivariable models showed greater odds of AUD for respondents with dual ENDS and cigarette use (AOR = 10.2), ENDS use (AOR = 6.27), cigarette use (AOR = 4.45), and a history, but not ongoing, use (AOR = 2.60) relative to respondents with no use history. Similarly, respondents with dual use (AOR = 3.94), ENDS use (AOR = 2.41), and cigarette use (AOR = 1.71) had greater odds of AUD relative to those with a history of, but not ongoing, use. The association between dual use and AUD was greater for adults ages 21-25 (AOR = 16.2) than for adults over 25 (AOR = 7.82). Cigarette and ENDS solo and dual-use were similarly associated with greater odds of alcohol-related risky behavior relative to control groups.nnCONCLUSION: These findings demonstrate that nicotine use and dual use may be associated with indicators of problematic drinking. These results offer insight into emerging licit polysubstance profiles and call for mechanistic research to inform prevention and intervention efforts.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37184943b,

title = {Temporal reliability and stability of delay discounting: A 2-year repeated assessments study of the Monetary Choice Questionnaire},

author = {Justin C Strickland and Brett W Gelino and Jill A Rabinowitz and Magdalene R Ford and Lauren Dayton and Carl Latkin and Derek D Reed},

doi = {10.1037/pha0000651},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {902--907},

abstract = {The Monetary Choice Questionnaire (MCQ) is one of the most commonly used measures to assess delay discounting of reward. Reliable measurement by the MCQ is necessary for use in experimental settings or prognostic validity within clinical contexts. The present analysis expands prior work to evaluate temporal reliability and stability over an extended period, including repeated measurements, a larger and more broadly representative sample, and demonstrations of covariation with clinically significant health behaviors (e.g., cigarette use, COVID-19 vaccination, body mass index). Participants ( = 680; 55.6% female) were recruited through crowdsourcing and completed the MCQ approximately quarterly over 2 years. Measures of reliability, stability, and correlations with clinical constructs were determined for each timepoint and pairwise comparison. Test-retest reliabilities were high across all pairwise comparisons (all  > .75; range = .78-.86; mean = .83). Stability was also high with within-subject effect size differences all within a less-than-small effect size range (range  = -0.09 to 0.19; mean = 0.04). Positive associations between smoking status and delay discounting rates were observed consistent with prior clinical studies. These findings of test durability support the use of MCQ administration for repeated measurement of delay-constrained choice as a stable respondent characteristic and illustrate its association with important health behaviors over extended time periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36634016,

title = {Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey},

author = {Oliver Grundmann and Charles A Veltri and Sara Morcos and Kirsten E Smith and Darshan Singh and Ornella Corazza and Eduardo Cinosi and Giovanni Martinotti and Zach Walsh and Marc T Swogger},

doi = {10.1037/pha0000632},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {963--977},

abstract = {Kratom ( Korth.) use has increased substantially over the past decade outside of its indigenous regions, especially for the self-treatment of psychiatric conditions. An anonymous, cross-sectional, online survey was completed by 4,945 people who use kratom (PWUK) between July 2019 and July 2020. A total of 2,296 respondents completed an extended survey that included clinical scales for measuring attention deficit hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD), depressive and anxiety disorders. PWUK and met criteria for ADHD, PTSD, depressive or anxiety disorders were primarily middle-aged (31-50 years), employed, college-level educated, and reported greater concurrent or prior use of kratom with cannabis, cannabidiol, and benzodiazepines. For all psychiatric conditions, PWUK reported decreased depressive and anxious moods than before kratom use. Based on this self-report study, observational and other clinical studies are warranted for kratom. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37184943,

title = {Temporal reliability and stability of delay discounting: A 2-year repeated assessments study of the Monetary Choice Questionnaire},

author = {Justin C Strickland and Brett W Gelino and Jill A Rabinowitz and Magdalene R Ford and Lauren Dayton and Carl Latkin and Derek D Reed},

doi = {10.1037/pha0000651},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {902--907},

abstract = {The Monetary Choice Questionnaire (MCQ) is one of the most commonly used measures to assess delay discounting of reward. Reliable measurement by the MCQ is necessary for use in experimental settings or prognostic validity within clinical contexts. The present analysis expands prior work to evaluate temporal reliability and stability over an extended period, including repeated measurements, a larger and more broadly representative sample, and demonstrations of covariation with clinically significant health behaviors (e.g., cigarette use, COVID-19 vaccination, body mass index). Participants ( = 680; 55.6% female) were recruited through crowdsourcing and completed the MCQ approximately quarterly over 2 years. Measures of reliability, stability, and correlations with clinical constructs were determined for each timepoint and pairwise comparison. Test-retest reliabilities were high across all pairwise comparisons (all  > .75; range = .78-.86; mean = .83). Stability was also high with within-subject effect size differences all within a less-than-small effect size range (range  = -0.09 to 0.19; mean = 0.04). Positive associations between smoking status and delay discounting rates were observed consistent with prior clinical studies. These findings of test durability support the use of MCQ administration for repeated measurement of delay-constrained choice as a stable respondent characteristic and illustrate its association with important health behaviors over extended time periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37541600,

title = {Abstinence-contingent wage supplements for adults experiencing homelessness and alcohol use disorder: A randomized clinical trial},

author = {Matthew D Novak and Forrest Toegel and August F Holtyn and Andrew M Rodewald and Meghan Arellano and Mackenzie Baranski and Nancy P Barnett and Jeannie-Marie Leoutsakos and Michael Fingerhood and Kenneth Silverman},

doi = {10.1016/j.ypmed.2023.107655},

issn = {1096-0260},

year  = {2023},

date = {2023-08-01},

journal = {Prev Med},

pages = {107655},

abstract = {This study evaluated the effectiveness of abstinence-contingent wage supplements in promoting alcohol abstinence and employment in adults experiencing homelessness and alcohol use disorder. A randomized clinical trial was conducted from 2019 to 2022. After a 1-month Induction period, 119 participants were randomly assigned to a Usual Care Control group (n = 57) or an Abstinence-Contingent Wage Supplement group (n = 62). Usual Care participants were offered counseling and referrals to employment and treatment programs. Abstinence-Contingent Wage Supplement participants could earn stipends for working with an employment specialist and wage supplements for working in a community job but had to maintain abstinence from alcohol as determined by transdermal alcohol concentration monitoring devices to maximize pay. Abstinence-Contingent Wage Supplement participants reported significantly higher rates of alcohol abstinence than Usual Care participants during the 6-month intervention (82.8% vs. 60.2% of months, OR = 3.4, 95% CI 1.8 to 6.3, p < .001). Abstinence-Contingent Wage Supplement participants were also significantly more likely to obtain employment (51.3% vs. 31.6% of months, OR = 2.6, 95% CI 1.5 to 4.4, p < .001) and live out of poverty (38.2% vs. 16.7% of months, OR = 3.7, 95% CI 2.0 to 7.1, p < .001) than Usual Care participants. These findings suggest that Abstinence-Contingent Wage Supplements can promote alcohol abstinence and employment in adults experiencing homelessness and alcohol use disorder. ClinicalTrials.gov Identifier: NCT03519009.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37594029,

title = {Adverse childhood experiences and early initiation of substance use: A survival analysis},

author = {Amy L Meadows and Justin C Strickland and S Maela Hyder and Rita C Basconi and Margaret E Stull and Frances P Wagner and Mai N Nguyen and Abner O Rayapati and Craig R Rush},

doi = {10.1177/00912174231195751},

issn = {1541-3527},

year  = {2023},

date = {2023-08-01},

journal = {Int J Psychiatry Med},

pages = {912174231195751},

abstract = {OBJECTIVE: Early adversity, such as adverse childhood experiences (ACEs), is a risk factor for the development of substance use disorder (SUD). ACEs are associated with earlier initiation of substance use. This study examines the relationship between ACEs and age of initiation of substance use using a survival analysis. It is hypothesized that individuals with higher ACEs will have an earlier age of initiation.nnMETHOD: Participants were recruited from the University of Kentucky's Laboratory for Human Behavioral Pharmacology. Participants were 18 years or older, English-speaking, and actively partaking in substance use. Participants were not in or seeking treatment for substance use. A paper screening protocol was completed. ACE scores were calculated and age of initiation was noted. A Cox proportional hazard model was used to predict substance use initiation by ACE score.nnRESULTS: A total of 107 responses were analyzed. An average number of 2.3 ACEs (SD = 2.2) were endorsed with 24% of participants reporting 4 or more ACEs. Higher ACE scores were associated with cigarette smoking and non-medical prescription opioid use onset, demonstrating a hazard ratio (HR) of 1.14 and 1.19, -value of .02 and .01, and 95% confidence intervals of (1.02, 1.28) and (1.04, 1.37) respectively.nnCONCLUSIONS: A significant association was found between higher ACE scores and earlier initiation of cigarette and non-medical prescription opioid use, consistent with prior research. Primary prevention of ACEs, screening, and intervention in childhood may be unique approaches to decrease the risk of substance use/SUD.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37487953,

title = {Role of social context in addiction etiology and recovery},

author = {Justin C Strickland and Samuel F Acuff},

doi = {10.1016/j.pbb.2023.173603},

issn = {1873-5177},

year  = {2023},

date = {2023-08-01},

journal = {Pharmacol Biochem Behav},

volume = {229},

pages = {173603},

abstract = {While social context has long been considered central to substance use disorder prevention and treatment and many drug-taking events occur in social settings, experimental research on social context has historically been limited. Recent years have seen an emergence of concerted preclinical and human laboratory research documenting the direct impact of social context on substance use, delineating behavioral and neurobiological mechanisms underlying social influence's role. We review this emerging preclinical and human laboratory literature from a theoretical lens that considers distinct stages of the addiction process including drug initiation/acquisition, escalation, and recovery. A key conclusion of existing research is that the impact of the social environment is critically moderated by the drug-taking behavior and drug use history of a social peer. Specifically, while drug-free social contexts can reduce the likelihood of drug use initiation and act as a competitive non-drug alternative preventing escalation, drug-using peers can equally facilitate initiation and escalation through peer modeling as a contingent reward of use. Likewise, social context may facilitate recovery or serve as a barrier that increases the chances of a return to regular use. We conclude by discussing evidence-based treatments and recovery support services that explicitly target social mechanisms or that have identified social context as a mechanism of change within treatment. Ultimately, new areas for research including the expansion of drug classes studied and novel human laboratory designs are needed to further translate emerging findings into clinical practice.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36649153,

title = {Social influence and the likelihood of using cannabis: Role of source physical attractiveness},

author = {Mark A Smith and Anna L Davis and Justin C Strickland},

doi = {10.1037/pha0000634},

issn = {1936-2293},

year  = {2023},

date = {2023-08-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {4},

pages = {799--804},

abstract = {The presence of another individual may increase or decrease the likelihood a person will use drugs, depending on factors such as whether the source (i.e., the other individual) is also using drugs. The purpose of this study was to determine whether the physical attractiveness of the source influences the likelihood a person will use cannabis. Heterosexual men and women were recruited via a crowdsourcing platform and asked to rank order the physical attractiveness of 13 opposite-gender people. Participants were then presented with hypothetical scenarios in which they reported the likelihood of engaging in drug use (i.e., "use marijuana") and a nondrug control activity ("enjoy the view" from a private balcony) when they were alone versus in the presence of an opposite-gender person they rated low, moderate, or high in relative physical attractiveness. The likelihood of participating in both drug and nondrug activities increased as a function of the relative physical attractiveness of the other individual (i.e., the source); however, notable gender differences were observed in the likelihood of using cannabis. Women were less likely to use cannabis in the presence of less attractive men relative to using cannabis alone, whereas men were more likely to use cannabis in the presence of more attractive women than using cannabis alone. These data suggest the presence of an opposite-gender person can either inhibit or facilitate drug use depending on the physical attractiveness of the source and gender of the subject. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37192690b,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A Rabinowitz and Jennifer D Ellis and Justin C Strickland and Martin Hochheimer and Yijun Zhou and Andrea S Young and Brenda Curtis and Andrew S Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {1573-2517},

year  = {2023},

date = {2023-08-01},

journal = {J Affect Disord},

volume = {335},

pages = {248--255},

abstract = {BACKGROUND: Although depressive symptoms represent a promising therapeutic target to promote recovery from substance use disorders (SUD), heterogeneity in their diagnostic presentation often hinders the ability to effectively tailor treatment. We sought to identify subgroups of individuals varying in depressive symptom phenotypes (i.e., demoralization, anhedonia), and examined whether these subgroups were associated with patient demographics, psychosocial health, and treatment attrition.nnMETHODS: Patients (N = 10,103, 69.2 % male) were drawn from a dataset of individuals who presented for admission to SUD treatment in the US. Participants reported on their demoralization and anhedonia approximately weekly for the first month of treatment, and on their demographics, psychosocial health, and primary substance at intake. Longitudinal latent profile analysis examined patterns of demoralization and anhedonia with treatment attrition as a distal outcome.nnRESULTS: Four subgroups of individuals emerged: (1) High demoralization and anhedonia, (2) Remitting demoralization and anhedonia, (3) High demoralization, low anhedonia, and (4) Low demoralization and anhedonia. Relative to the Low demoralization and anhedonia subgroup, all the other profiles were more likely to discontinue treatment. Numerous between-profile differences were observed with regard to demographics, psychosocial health, and primary substance.nnLIMITATIONS: The racial and ethnic background of the sample was skewed towards White individuals; future research is needed to determine the generalizability of our findings to minoritized racial and ethnic groups.nnCONCLUSIONS: We identified four clinical profiles that varied in the joint course of demoralization and anhedonia. Findings suggest specific subgroups might benefit from additional interventions and treatments that address their unique mental health needs during SUD recovery.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37192690,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A Rabinowitz and Jennifer D Ellis and Justin C Strickland and Martin Hochheimer and Yijun Zhou and Andrea S Young and Brenda Curtis and Andrew S Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {1573-2517},

year  = {2023},

date = {2023-08-01},

journal = {J Affect Disord},

volume = {335},

pages = {248--255},

abstract = {BACKGROUND: Although depressive symptoms represent a promising therapeutic target to promote recovery from substance use disorders (SUD), heterogeneity in their diagnostic presentation often hinders the ability to effectively tailor treatment. We sought to identify subgroups of individuals varying in depressive symptom phenotypes (i.e., demoralization, anhedonia), and examined whether these subgroups were associated with patient demographics, psychosocial health, and treatment attrition.nnMETHODS: Patients (N = 10,103, 69.2 % male) were drawn from a dataset of individuals who presented for admission to SUD treatment in the US. Participants reported on their demoralization and anhedonia approximately weekly for the first month of treatment, and on their demographics, psychosocial health, and primary substance at intake. Longitudinal latent profile analysis examined patterns of demoralization and anhedonia with treatment attrition as a distal outcome.nnRESULTS: Four subgroups of individuals emerged: (1) High demoralization and anhedonia, (2) Remitting demoralization and anhedonia, (3) High demoralization, low anhedonia, and (4) Low demoralization and anhedonia. Relative to the Low demoralization and anhedonia subgroup, all the other profiles were more likely to discontinue treatment. Numerous between-profile differences were observed with regard to demographics, psychosocial health, and primary substance.nnLIMITATIONS: The racial and ethnic background of the sample was skewed towards White individuals; future research is needed to determine the generalizability of our findings to minoritized racial and ethnic groups.nnCONCLUSIONS: We identified four clinical profiles that varied in the joint course of demoralization and anhedonia. Findings suggest specific subgroups might benefit from additional interventions and treatments that address their unique mental health needs during SUD recovery.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rabinowitz2023,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A. Rabinowitz and Jennifer D. Ellis and Justin C. Strickland and Martin Hochheimer and Yijun Zhou and Andrea S. Young and Brenda Curtis and Andrew S. Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {0165-0327},

year  = {2023},

date = {2023-08-00},

journal = {Journal of Affective Disorders},

volume = {335},

pages = {248--255},

publisher = {Elsevier BV},

keywords = {Clinical Psychology, Psychiatry and Mental health},

pubstate = {published},

tppubtype = {article}

}

@article{Resko2023b,

title = {Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids},

author = {Stella M. Resko and Emily Pasman and Danielle L. Hicks and Guijin Lee and Jennifer D. Ellis and Sydney O’Shay and Suzanne Brown and Elizabeth Agius},

doi = {10.1007/s10900-023-01257-x},

issn = {1573-3610},

year  = {2023},

date = {2023-07-14},

journal = {J Community Health},

publisher = {Springer Science and Business Media LLC},

keywords = {Environmental and Occupational Health, Health (social science), Public Health},

pubstate = {published},

tppubtype = {article}

}

@article{Resko2023,

title = {Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids},

author = {Stella M. Resko and Emily Pasman and Danielle L. Hicks and Guijin Lee and Jennifer D. Ellis and Sydney O’Shay and Suzanne Brown and Elizabeth Agius},

doi = {10.1007/s10900-023-01257-x},

issn = {1573-3610},

year  = {2023},

date = {2023-07-14},

journal = {J Community Health},

publisher = {Springer Science and Business Media LLC},

keywords = {Environmental and Occupational Health, Health (social science), Public Health},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37182354b,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D Ellis and Jill A Rabinowitz and Justin C Strickland and Neha Skandan and J Gregory Hobelmann and Patrick H Finan and Andrew S Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {1879-0046},

year  = {2023},

date = {2023-07-01},

journal = {Drug Alcohol Depend},

volume = {248},

pages = {109903},

abstract = {AIM: Sleep disturbance, clinically significant pain, and depressive symptoms commonly occur together among individuals with substance use disorders. The purposes of the present study were to 1) identify subgroups of individuals with heterogenous patterns of pain, sleep disturbance, and depressive symptoms, and 2) identify demographic and clinical correlates of profile membership.nnMATERIAL AND METHODS: The present study assessed a sample (N = 8621) of individuals seeking residential substance use treatment in 2020 and 2021 in the United States. We examined whether unique sub-groups could be identified based on patterns of sleep disturbance, pain impact, and depressive symptoms during the first four weeks of treatment, using longitudinal latent profile analysis. Next, we explored demographic, substance use, and clinical correlates (i.e., distress intolerance) of profile membership, as well as whether profile membership was associated with treatment attrition.nnRESULTS: The identified classes were: 1) Low sleep disturbance, pain impact, and depressive symptoms, 2) High pain, remitting depressive symptoms, and mild sleep disturbance, 3) High depressive symptoms, low pain, and remitting sleep disturbance, and 4) High sleep disturbance, pain impact, and depressive symptoms. Individuals with high pain, depressive symptoms, and sleep disturbance were more likely to be older, use opioids as their primary substance, have high distress intolerance, and discontinue treatment.nnCONCLUSION: Results highlight the importance of comprehensive care and management of physical health conditions, particularly among older adults. Further, results highlight that distress intolerance may be a modifiable risk factor for co-occurring sleep disturbance, pain impact, and depressive symptoms.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37085021,

title = {The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review},

author = {Manoj K Doss and Harriet de Wit and David A Gallo},

doi = {10.1016/j.neubiorev.2023.105188},

issn = {1873-7528},

year  = {2023},

date = {2023-07-01},

journal = {Neurosci Biobehav Rev},

volume = {150},

pages = {105188},

abstract = {Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic memories, specifically encoding (forming memories), consolidation (stabilizing memories), and retrieval (accessing memories). Drugs administered before encoding may preferentially impair (e.g., GABA sedatives including alcohol and benzodiazepines, Δ-tetrahydrocannabinol or THC, ketamine), enhance (e.g., dextroamphetamine and dextromethamphetamine), or both impair and enhance (i.e., ± 3,4-methylenedioxymethylamphetamine or MDMA) emotionally negative and positive compared to neutral memories. GABA sedatives administered immediately post-encoding (during consolidation) can preferentially enhance emotional memories, though this selectivity may decline or even reverse (i.e., preferential enhancement of neutral memories) as the delay between encoding and retrieval increases. Finally, retrieving memories under the effects of THC, dextroamphetamine, MDMA, and perhaps GABA sedatives distorts memory, with potentially greater selectively for emotional (especially positive) memories. We review these effects, propose neural mechanisms, discuss methodological considerations for future work, and speculate how drug effects on emotional episodic memory may contribute to drug use and abuse.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37182354,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D Ellis and Jill A Rabinowitz and Justin C Strickland and Neha Skandan and J Gregory Hobelmann and Patrick H Finan and Andrew S Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {1879-0046},

year  = {2023},

date = {2023-07-01},

journal = {Drug Alcohol Depend},

volume = {248},

pages = {109903},

abstract = {AIM: Sleep disturbance, clinically significant pain, and depressive symptoms commonly occur together among individuals with substance use disorders. The purposes of the present study were to 1) identify subgroups of individuals with heterogenous patterns of pain, sleep disturbance, and depressive symptoms, and 2) identify demographic and clinical correlates of profile membership.nnMATERIAL AND METHODS: The present study assessed a sample (N = 8621) of individuals seeking residential substance use treatment in 2020 and 2021 in the United States. We examined whether unique sub-groups could be identified based on patterns of sleep disturbance, pain impact, and depressive symptoms during the first four weeks of treatment, using longitudinal latent profile analysis. Next, we explored demographic, substance use, and clinical correlates (i.e., distress intolerance) of profile membership, as well as whether profile membership was associated with treatment attrition.nnRESULTS: The identified classes were: 1) Low sleep disturbance, pain impact, and depressive symptoms, 2) High pain, remitting depressive symptoms, and mild sleep disturbance, 3) High depressive symptoms, low pain, and remitting sleep disturbance, and 4) High sleep disturbance, pain impact, and depressive symptoms. Individuals with high pain, depressive symptoms, and sleep disturbance were more likely to be older, use opioids as their primary substance, have high distress intolerance, and discontinue treatment.nnCONCLUSION: Results highlight the importance of comprehensive care and management of physical health conditions, particularly among older adults. Further, results highlight that distress intolerance may be a modifiable risk factor for co-occurring sleep disturbance, pain impact, and depressive symptoms.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023c,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D. Ellis and Jill A. Rabinowitz. and Justin C. Strickland and Neha Skandan and J. Gregory Hobelmann and Patrick H. Finan and Andrew S. Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {0376-8716},

year  = {2023},

date = {2023-07-00},

journal = {Drug and Alcohol Dependence},

volume = {248},

publisher = {Elsevier BV},

keywords = {Pharmacology, Pharmacology (medical), Psychiatry and Mental health, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023b,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D. Ellis and Jill A. Rabinowitz. and Justin C. Strickland and Neha Skandan and J. Gregory Hobelmann and Patrick H. Finan and Andrew S. Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {0376-8716},

year  = {2023},

date = {2023-07-00},

journal = {Drug and Alcohol Dependence},

volume = {248},

publisher = {Elsevier BV},

keywords = {Pharmacology, Pharmacology (medical), Psychiatry and Mental health, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37397437,

title = {Kratom withdrawal: Discussions and conclusions of a scientific expert forum},

author = {Jack E Henningfield and Marek C Chawarski and Albert Garcia-Romeu and Oliver Grundmann and Norsyifa Harun and Zurina Hassan and Christopher R McCurdy and Lance R McMahon and Abhisheak Sharma and Mohammed Shoaib and Darshan Singh and Kirsten E Smith and Marc T Swogger and Balasingam Vicknasingam and Zachary Walsh and Daniel W Wang and Marilyn A Huestis},

doi = {10.1016/j.dadr.2023.100142},

issn = {2772-7246},

year  = {2023},

date = {2023-06-01},

journal = {Drug Alcohol Depend Rep},

volume = {7},

pages = {100142},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37473614b,

title = {Association of electronic nicotine delivery system (ENDS) and cigarette solo and dual use with alcohol-related consequences among US adults},

author = {Brett W Gelino and Derek D Reed and Tory R Spindle and Michael Amlung and Justin C Strickland},

doi = {10.1016/j.addbeh.2023.107806},

issn = {1873-6327},

year  = {2023},

date = {2023-11-01},

journal = {Addict Behav},

volume = {146},

pages = {107806},

abstract = {INTRODUCTION: Research reports a robust association between combustible cigarette use and alcohol use frequency and severity. Extension to the emerging landscape of electronic nicotine delivery system (ENDS) use is needed to inform prevention and treatment strategies.nnMETHOD: We evaluated data from the 2020 National Survey on Drug Use and Health (NSDUH). Respondents included adults reporting cigarettes or ENDS solo or dual use. Multivariable logistic regression models evaluated associations with alcohol use disorder (AUD) and alcohol-related risky behavior (i.e., heavy drinking, binge alcohol use, and driving after drinking) compared to never use controls and respondents with a history, but not current, use of cigarettes or ENDS.nnRESULTS: Multivariable models showed greater odds of AUD for respondents with dual ENDS and cigarette use (AOR = 10.2), ENDS use (AOR = 6.27), cigarette use (AOR = 4.45), and a history, but not ongoing, use (AOR = 2.60) relative to respondents with no use history. Similarly, respondents with dual use (AOR = 3.94), ENDS use (AOR = 2.41), and cigarette use (AOR = 1.71) had greater odds of AUD relative to those with a history of, but not ongoing, use. The association between dual use and AUD was greater for adults ages 21-25 (AOR = 16.2) than for adults over 25 (AOR = 7.82). Cigarette and ENDS solo and dual-use were similarly associated with greater odds of alcohol-related risky behavior relative to control groups.nnCONCLUSION: These findings demonstrate that nicotine use and dual use may be associated with indicators of problematic drinking. These results offer insight into emerging licit polysubstance profiles and call for mechanistic research to inform prevention and intervention efforts.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37473614,

title = {Association of electronic nicotine delivery system (ENDS) and cigarette solo and dual use with alcohol-related consequences among US adults},

author = {Brett W Gelino and Derek D Reed and Tory R Spindle and Michael Amlung and Justin C Strickland},

doi = {10.1016/j.addbeh.2023.107806},

issn = {1873-6327},

year  = {2023},

date = {2023-11-01},

journal = {Addict Behav},

volume = {146},

pages = {107806},

abstract = {INTRODUCTION: Research reports a robust association between combustible cigarette use and alcohol use frequency and severity. Extension to the emerging landscape of electronic nicotine delivery system (ENDS) use is needed to inform prevention and treatment strategies.nnMETHOD: We evaluated data from the 2020 National Survey on Drug Use and Health (NSDUH). Respondents included adults reporting cigarettes or ENDS solo or dual use. Multivariable logistic regression models evaluated associations with alcohol use disorder (AUD) and alcohol-related risky behavior (i.e., heavy drinking, binge alcohol use, and driving after drinking) compared to never use controls and respondents with a history, but not current, use of cigarettes or ENDS.nnRESULTS: Multivariable models showed greater odds of AUD for respondents with dual ENDS and cigarette use (AOR = 10.2), ENDS use (AOR = 6.27), cigarette use (AOR = 4.45), and a history, but not ongoing, use (AOR = 2.60) relative to respondents with no use history. Similarly, respondents with dual use (AOR = 3.94), ENDS use (AOR = 2.41), and cigarette use (AOR = 1.71) had greater odds of AUD relative to those with a history of, but not ongoing, use. The association between dual use and AUD was greater for adults ages 21-25 (AOR = 16.2) than for adults over 25 (AOR = 7.82). Cigarette and ENDS solo and dual-use were similarly associated with greater odds of alcohol-related risky behavior relative to control groups.nnCONCLUSION: These findings demonstrate that nicotine use and dual use may be associated with indicators of problematic drinking. These results offer insight into emerging licit polysubstance profiles and call for mechanistic research to inform prevention and intervention efforts.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37184943b,

title = {Temporal reliability and stability of delay discounting: A 2-year repeated assessments study of the Monetary Choice Questionnaire},

author = {Justin C Strickland and Brett W Gelino and Jill A Rabinowitz and Magdalene R Ford and Lauren Dayton and Carl Latkin and Derek D Reed},

doi = {10.1037/pha0000651},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {902--907},

abstract = {The Monetary Choice Questionnaire (MCQ) is one of the most commonly used measures to assess delay discounting of reward. Reliable measurement by the MCQ is necessary for use in experimental settings or prognostic validity within clinical contexts. The present analysis expands prior work to evaluate temporal reliability and stability over an extended period, including repeated measurements, a larger and more broadly representative sample, and demonstrations of covariation with clinically significant health behaviors (e.g., cigarette use, COVID-19 vaccination, body mass index). Participants ( = 680; 55.6% female) were recruited through crowdsourcing and completed the MCQ approximately quarterly over 2 years. Measures of reliability, stability, and correlations with clinical constructs were determined for each timepoint and pairwise comparison. Test-retest reliabilities were high across all pairwise comparisons (all  > .75; range = .78-.86; mean = .83). Stability was also high with within-subject effect size differences all within a less-than-small effect size range (range  = -0.09 to 0.19; mean = 0.04). Positive associations between smoking status and delay discounting rates were observed consistent with prior clinical studies. These findings of test durability support the use of MCQ administration for repeated measurement of delay-constrained choice as a stable respondent characteristic and illustrate its association with important health behaviors over extended time periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36634016,

title = {Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey},

author = {Oliver Grundmann and Charles A Veltri and Sara Morcos and Kirsten E Smith and Darshan Singh and Ornella Corazza and Eduardo Cinosi and Giovanni Martinotti and Zach Walsh and Marc T Swogger},

doi = {10.1037/pha0000632},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {963--977},

abstract = {Kratom ( Korth.) use has increased substantially over the past decade outside of its indigenous regions, especially for the self-treatment of psychiatric conditions. An anonymous, cross-sectional, online survey was completed by 4,945 people who use kratom (PWUK) between July 2019 and July 2020. A total of 2,296 respondents completed an extended survey that included clinical scales for measuring attention deficit hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD), depressive and anxiety disorders. PWUK and met criteria for ADHD, PTSD, depressive or anxiety disorders were primarily middle-aged (31-50 years), employed, college-level educated, and reported greater concurrent or prior use of kratom with cannabis, cannabidiol, and benzodiazepines. For all psychiatric conditions, PWUK reported decreased depressive and anxious moods than before kratom use. Based on this self-report study, observational and other clinical studies are warranted for kratom. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37184943,

title = {Temporal reliability and stability of delay discounting: A 2-year repeated assessments study of the Monetary Choice Questionnaire},

author = {Justin C Strickland and Brett W Gelino and Jill A Rabinowitz and Magdalene R Ford and Lauren Dayton and Carl Latkin and Derek D Reed},

doi = {10.1037/pha0000651},

issn = {1936-2293},

year  = {2023},

date = {2023-10-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {5},

pages = {902--907},

abstract = {The Monetary Choice Questionnaire (MCQ) is one of the most commonly used measures to assess delay discounting of reward. Reliable measurement by the MCQ is necessary for use in experimental settings or prognostic validity within clinical contexts. The present analysis expands prior work to evaluate temporal reliability and stability over an extended period, including repeated measurements, a larger and more broadly representative sample, and demonstrations of covariation with clinically significant health behaviors (e.g., cigarette use, COVID-19 vaccination, body mass index). Participants ( = 680; 55.6% female) were recruited through crowdsourcing and completed the MCQ approximately quarterly over 2 years. Measures of reliability, stability, and correlations with clinical constructs were determined for each timepoint and pairwise comparison. Test-retest reliabilities were high across all pairwise comparisons (all  > .75; range = .78-.86; mean = .83). Stability was also high with within-subject effect size differences all within a less-than-small effect size range (range  = -0.09 to 0.19; mean = 0.04). Positive associations between smoking status and delay discounting rates were observed consistent with prior clinical studies. These findings of test durability support the use of MCQ administration for repeated measurement of delay-constrained choice as a stable respondent characteristic and illustrate its association with important health behaviors over extended time periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37541600,

title = {Abstinence-contingent wage supplements for adults experiencing homelessness and alcohol use disorder: A randomized clinical trial},

author = {Matthew D Novak and Forrest Toegel and August F Holtyn and Andrew M Rodewald and Meghan Arellano and Mackenzie Baranski and Nancy P Barnett and Jeannie-Marie Leoutsakos and Michael Fingerhood and Kenneth Silverman},

doi = {10.1016/j.ypmed.2023.107655},

issn = {1096-0260},

year  = {2023},

date = {2023-08-01},

journal = {Prev Med},

pages = {107655},

abstract = {This study evaluated the effectiveness of abstinence-contingent wage supplements in promoting alcohol abstinence and employment in adults experiencing homelessness and alcohol use disorder. A randomized clinical trial was conducted from 2019 to 2022. After a 1-month Induction period, 119 participants were randomly assigned to a Usual Care Control group (n = 57) or an Abstinence-Contingent Wage Supplement group (n = 62). Usual Care participants were offered counseling and referrals to employment and treatment programs. Abstinence-Contingent Wage Supplement participants could earn stipends for working with an employment specialist and wage supplements for working in a community job but had to maintain abstinence from alcohol as determined by transdermal alcohol concentration monitoring devices to maximize pay. Abstinence-Contingent Wage Supplement participants reported significantly higher rates of alcohol abstinence than Usual Care participants during the 6-month intervention (82.8% vs. 60.2% of months, OR = 3.4, 95% CI 1.8 to 6.3, p < .001). Abstinence-Contingent Wage Supplement participants were also significantly more likely to obtain employment (51.3% vs. 31.6% of months, OR = 2.6, 95% CI 1.5 to 4.4, p < .001) and live out of poverty (38.2% vs. 16.7% of months, OR = 3.7, 95% CI 2.0 to 7.1, p < .001) than Usual Care participants. These findings suggest that Abstinence-Contingent Wage Supplements can promote alcohol abstinence and employment in adults experiencing homelessness and alcohol use disorder. ClinicalTrials.gov Identifier: NCT03519009.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37594029,

title = {Adverse childhood experiences and early initiation of substance use: A survival analysis},

author = {Amy L Meadows and Justin C Strickland and S Maela Hyder and Rita C Basconi and Margaret E Stull and Frances P Wagner and Mai N Nguyen and Abner O Rayapati and Craig R Rush},

doi = {10.1177/00912174231195751},

issn = {1541-3527},

year  = {2023},

date = {2023-08-01},

journal = {Int J Psychiatry Med},

pages = {912174231195751},

abstract = {OBJECTIVE: Early adversity, such as adverse childhood experiences (ACEs), is a risk factor for the development of substance use disorder (SUD). ACEs are associated with earlier initiation of substance use. This study examines the relationship between ACEs and age of initiation of substance use using a survival analysis. It is hypothesized that individuals with higher ACEs will have an earlier age of initiation.nnMETHOD: Participants were recruited from the University of Kentucky's Laboratory for Human Behavioral Pharmacology. Participants were 18 years or older, English-speaking, and actively partaking in substance use. Participants were not in or seeking treatment for substance use. A paper screening protocol was completed. ACE scores were calculated and age of initiation was noted. A Cox proportional hazard model was used to predict substance use initiation by ACE score.nnRESULTS: A total of 107 responses were analyzed. An average number of 2.3 ACEs (SD = 2.2) were endorsed with 24% of participants reporting 4 or more ACEs. Higher ACE scores were associated with cigarette smoking and non-medical prescription opioid use onset, demonstrating a hazard ratio (HR) of 1.14 and 1.19, -value of .02 and .01, and 95% confidence intervals of (1.02, 1.28) and (1.04, 1.37) respectively.nnCONCLUSIONS: A significant association was found between higher ACE scores and earlier initiation of cigarette and non-medical prescription opioid use, consistent with prior research. Primary prevention of ACEs, screening, and intervention in childhood may be unique approaches to decrease the risk of substance use/SUD.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37487953,

title = {Role of social context in addiction etiology and recovery},

author = {Justin C Strickland and Samuel F Acuff},

doi = {10.1016/j.pbb.2023.173603},

issn = {1873-5177},

year  = {2023},

date = {2023-08-01},

journal = {Pharmacol Biochem Behav},

volume = {229},

pages = {173603},

abstract = {While social context has long been considered central to substance use disorder prevention and treatment and many drug-taking events occur in social settings, experimental research on social context has historically been limited. Recent years have seen an emergence of concerted preclinical and human laboratory research documenting the direct impact of social context on substance use, delineating behavioral and neurobiological mechanisms underlying social influence's role. We review this emerging preclinical and human laboratory literature from a theoretical lens that considers distinct stages of the addiction process including drug initiation/acquisition, escalation, and recovery. A key conclusion of existing research is that the impact of the social environment is critically moderated by the drug-taking behavior and drug use history of a social peer. Specifically, while drug-free social contexts can reduce the likelihood of drug use initiation and act as a competitive non-drug alternative preventing escalation, drug-using peers can equally facilitate initiation and escalation through peer modeling as a contingent reward of use. Likewise, social context may facilitate recovery or serve as a barrier that increases the chances of a return to regular use. We conclude by discussing evidence-based treatments and recovery support services that explicitly target social mechanisms or that have identified social context as a mechanism of change within treatment. Ultimately, new areas for research including the expansion of drug classes studied and novel human laboratory designs are needed to further translate emerging findings into clinical practice.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36649153,

title = {Social influence and the likelihood of using cannabis: Role of source physical attractiveness},

author = {Mark A Smith and Anna L Davis and Justin C Strickland},

doi = {10.1037/pha0000634},

issn = {1936-2293},

year  = {2023},

date = {2023-08-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {4},

pages = {799--804},

abstract = {The presence of another individual may increase or decrease the likelihood a person will use drugs, depending on factors such as whether the source (i.e., the other individual) is also using drugs. The purpose of this study was to determine whether the physical attractiveness of the source influences the likelihood a person will use cannabis. Heterosexual men and women were recruited via a crowdsourcing platform and asked to rank order the physical attractiveness of 13 opposite-gender people. Participants were then presented with hypothetical scenarios in which they reported the likelihood of engaging in drug use (i.e., "use marijuana") and a nondrug control activity ("enjoy the view" from a private balcony) when they were alone versus in the presence of an opposite-gender person they rated low, moderate, or high in relative physical attractiveness. The likelihood of participating in both drug and nondrug activities increased as a function of the relative physical attractiveness of the other individual (i.e., the source); however, notable gender differences were observed in the likelihood of using cannabis. Women were less likely to use cannabis in the presence of less attractive men relative to using cannabis alone, whereas men were more likely to use cannabis in the presence of more attractive women than using cannabis alone. These data suggest the presence of an opposite-gender person can either inhibit or facilitate drug use depending on the physical attractiveness of the source and gender of the subject. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37192690b,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A Rabinowitz and Jennifer D Ellis and Justin C Strickland and Martin Hochheimer and Yijun Zhou and Andrea S Young and Brenda Curtis and Andrew S Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {1573-2517},

year  = {2023},

date = {2023-08-01},

journal = {J Affect Disord},

volume = {335},

pages = {248--255},

abstract = {BACKGROUND: Although depressive symptoms represent a promising therapeutic target to promote recovery from substance use disorders (SUD), heterogeneity in their diagnostic presentation often hinders the ability to effectively tailor treatment. We sought to identify subgroups of individuals varying in depressive symptom phenotypes (i.e., demoralization, anhedonia), and examined whether these subgroups were associated with patient demographics, psychosocial health, and treatment attrition.nnMETHODS: Patients (N = 10,103, 69.2 % male) were drawn from a dataset of individuals who presented for admission to SUD treatment in the US. Participants reported on their demoralization and anhedonia approximately weekly for the first month of treatment, and on their demographics, psychosocial health, and primary substance at intake. Longitudinal latent profile analysis examined patterns of demoralization and anhedonia with treatment attrition as a distal outcome.nnRESULTS: Four subgroups of individuals emerged: (1) High demoralization and anhedonia, (2) Remitting demoralization and anhedonia, (3) High demoralization, low anhedonia, and (4) Low demoralization and anhedonia. Relative to the Low demoralization and anhedonia subgroup, all the other profiles were more likely to discontinue treatment. Numerous between-profile differences were observed with regard to demographics, psychosocial health, and primary substance.nnLIMITATIONS: The racial and ethnic background of the sample was skewed towards White individuals; future research is needed to determine the generalizability of our findings to minoritized racial and ethnic groups.nnCONCLUSIONS: We identified four clinical profiles that varied in the joint course of demoralization and anhedonia. Findings suggest specific subgroups might benefit from additional interventions and treatments that address their unique mental health needs during SUD recovery.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37192690,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A Rabinowitz and Jennifer D Ellis and Justin C Strickland and Martin Hochheimer and Yijun Zhou and Andrea S Young and Brenda Curtis and Andrew S Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {1573-2517},

year  = {2023},

date = {2023-08-01},

journal = {J Affect Disord},

volume = {335},

pages = {248--255},

abstract = {BACKGROUND: Although depressive symptoms represent a promising therapeutic target to promote recovery from substance use disorders (SUD), heterogeneity in their diagnostic presentation often hinders the ability to effectively tailor treatment. We sought to identify subgroups of individuals varying in depressive symptom phenotypes (i.e., demoralization, anhedonia), and examined whether these subgroups were associated with patient demographics, psychosocial health, and treatment attrition.nnMETHODS: Patients (N = 10,103, 69.2 % male) were drawn from a dataset of individuals who presented for admission to SUD treatment in the US. Participants reported on their demoralization and anhedonia approximately weekly for the first month of treatment, and on their demographics, psychosocial health, and primary substance at intake. Longitudinal latent profile analysis examined patterns of demoralization and anhedonia with treatment attrition as a distal outcome.nnRESULTS: Four subgroups of individuals emerged: (1) High demoralization and anhedonia, (2) Remitting demoralization and anhedonia, (3) High demoralization, low anhedonia, and (4) Low demoralization and anhedonia. Relative to the Low demoralization and anhedonia subgroup, all the other profiles were more likely to discontinue treatment. Numerous between-profile differences were observed with regard to demographics, psychosocial health, and primary substance.nnLIMITATIONS: The racial and ethnic background of the sample was skewed towards White individuals; future research is needed to determine the generalizability of our findings to minoritized racial and ethnic groups.nnCONCLUSIONS: We identified four clinical profiles that varied in the joint course of demoralization and anhedonia. Findings suggest specific subgroups might benefit from additional interventions and treatments that address their unique mental health needs during SUD recovery.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rabinowitz2023,

title = {Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition},

author = {Jill A. Rabinowitz and Jennifer D. Ellis and Justin C. Strickland and Martin Hochheimer and Yijun Zhou and Andrea S. Young and Brenda Curtis and Andrew S. Huhn},

doi = {10.1016/j.jad.2023.05.029},

issn = {0165-0327},

year  = {2023},

date = {2023-08-00},

journal = {Journal of Affective Disorders},

volume = {335},

pages = {248--255},

publisher = {Elsevier BV},

keywords = {Clinical Psychology, Psychiatry and Mental health},

pubstate = {published},

tppubtype = {article}

}

@article{Resko2023b,

title = {Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids},

author = {Stella M. Resko and Emily Pasman and Danielle L. Hicks and Guijin Lee and Jennifer D. Ellis and Sydney O’Shay and Suzanne Brown and Elizabeth Agius},

doi = {10.1007/s10900-023-01257-x},

issn = {1573-3610},

year  = {2023},

date = {2023-07-14},

journal = {J Community Health},

publisher = {Springer Science and Business Media LLC},

keywords = {Environmental and Occupational Health, Health (social science), Public Health},

pubstate = {published},

tppubtype = {article}

}

@article{Resko2023,

title = {Naloxone Knowledge and Attitudes Towards Overdose Response Among Family Members of People who Misuse Opioids},

author = {Stella M. Resko and Emily Pasman and Danielle L. Hicks and Guijin Lee and Jennifer D. Ellis and Sydney O’Shay and Suzanne Brown and Elizabeth Agius},

doi = {10.1007/s10900-023-01257-x},

issn = {1573-3610},

year  = {2023},

date = {2023-07-14},

journal = {J Community Health},

publisher = {Springer Science and Business Media LLC},

keywords = {Environmental and Occupational Health, Health (social science), Public Health},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37182354b,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D Ellis and Jill A Rabinowitz and Justin C Strickland and Neha Skandan and J Gregory Hobelmann and Patrick H Finan and Andrew S Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {1879-0046},

year  = {2023},

date = {2023-07-01},

journal = {Drug Alcohol Depend},

volume = {248},

pages = {109903},

abstract = {AIM: Sleep disturbance, clinically significant pain, and depressive symptoms commonly occur together among individuals with substance use disorders. The purposes of the present study were to 1) identify subgroups of individuals with heterogenous patterns of pain, sleep disturbance, and depressive symptoms, and 2) identify demographic and clinical correlates of profile membership.nnMATERIAL AND METHODS: The present study assessed a sample (N = 8621) of individuals seeking residential substance use treatment in 2020 and 2021 in the United States. We examined whether unique sub-groups could be identified based on patterns of sleep disturbance, pain impact, and depressive symptoms during the first four weeks of treatment, using longitudinal latent profile analysis. Next, we explored demographic, substance use, and clinical correlates (i.e., distress intolerance) of profile membership, as well as whether profile membership was associated with treatment attrition.nnRESULTS: The identified classes were: 1) Low sleep disturbance, pain impact, and depressive symptoms, 2) High pain, remitting depressive symptoms, and mild sleep disturbance, 3) High depressive symptoms, low pain, and remitting sleep disturbance, and 4) High sleep disturbance, pain impact, and depressive symptoms. Individuals with high pain, depressive symptoms, and sleep disturbance were more likely to be older, use opioids as their primary substance, have high distress intolerance, and discontinue treatment.nnCONCLUSION: Results highlight the importance of comprehensive care and management of physical health conditions, particularly among older adults. Further, results highlight that distress intolerance may be a modifiable risk factor for co-occurring sleep disturbance, pain impact, and depressive symptoms.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37085021,

title = {The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review},

author = {Manoj K Doss and Harriet de Wit and David A Gallo},

doi = {10.1016/j.neubiorev.2023.105188},

issn = {1873-7528},

year  = {2023},

date = {2023-07-01},

journal = {Neurosci Biobehav Rev},

volume = {150},

pages = {105188},

abstract = {Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic memories, specifically encoding (forming memories), consolidation (stabilizing memories), and retrieval (accessing memories). Drugs administered before encoding may preferentially impair (e.g., GABA sedatives including alcohol and benzodiazepines, Δ-tetrahydrocannabinol or THC, ketamine), enhance (e.g., dextroamphetamine and dextromethamphetamine), or both impair and enhance (i.e., ± 3,4-methylenedioxymethylamphetamine or MDMA) emotionally negative and positive compared to neutral memories. GABA sedatives administered immediately post-encoding (during consolidation) can preferentially enhance emotional memories, though this selectivity may decline or even reverse (i.e., preferential enhancement of neutral memories) as the delay between encoding and retrieval increases. Finally, retrieving memories under the effects of THC, dextroamphetamine, MDMA, and perhaps GABA sedatives distorts memory, with potentially greater selectively for emotional (especially positive) memories. We review these effects, propose neural mechanisms, discuss methodological considerations for future work, and speculate how drug effects on emotional episodic memory may contribute to drug use and abuse.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37182354,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D Ellis and Jill A Rabinowitz and Justin C Strickland and Neha Skandan and J Gregory Hobelmann and Patrick H Finan and Andrew S Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {1879-0046},

year  = {2023},

date = {2023-07-01},

journal = {Drug Alcohol Depend},

volume = {248},

pages = {109903},

abstract = {AIM: Sleep disturbance, clinically significant pain, and depressive symptoms commonly occur together among individuals with substance use disorders. The purposes of the present study were to 1) identify subgroups of individuals with heterogenous patterns of pain, sleep disturbance, and depressive symptoms, and 2) identify demographic and clinical correlates of profile membership.nnMATERIAL AND METHODS: The present study assessed a sample (N = 8621) of individuals seeking residential substance use treatment in 2020 and 2021 in the United States. We examined whether unique sub-groups could be identified based on patterns of sleep disturbance, pain impact, and depressive symptoms during the first four weeks of treatment, using longitudinal latent profile analysis. Next, we explored demographic, substance use, and clinical correlates (i.e., distress intolerance) of profile membership, as well as whether profile membership was associated with treatment attrition.nnRESULTS: The identified classes were: 1) Low sleep disturbance, pain impact, and depressive symptoms, 2) High pain, remitting depressive symptoms, and mild sleep disturbance, 3) High depressive symptoms, low pain, and remitting sleep disturbance, and 4) High sleep disturbance, pain impact, and depressive symptoms. Individuals with high pain, depressive symptoms, and sleep disturbance were more likely to be older, use opioids as their primary substance, have high distress intolerance, and discontinue treatment.nnCONCLUSION: Results highlight the importance of comprehensive care and management of physical health conditions, particularly among older adults. Further, results highlight that distress intolerance may be a modifiable risk factor for co-occurring sleep disturbance, pain impact, and depressive symptoms.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023c,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D. Ellis and Jill A. Rabinowitz. and Justin C. Strickland and Neha Skandan and J. Gregory Hobelmann and Patrick H. Finan and Andrew S. Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {0376-8716},

year  = {2023},

date = {2023-07-00},

journal = {Drug and Alcohol Dependence},

volume = {248},

publisher = {Elsevier BV},

keywords = {Pharmacology, Pharmacology (medical), Psychiatry and Mental health, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023b,

title = {Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment},

author = {Jennifer D. Ellis and Jill A. Rabinowitz. and Justin C. Strickland and Neha Skandan and J. Gregory Hobelmann and Patrick H. Finan and Andrew S. Huhn},

doi = {10.1016/j.drugalcdep.2023.109903},

issn = {0376-8716},

year  = {2023},

date = {2023-07-00},

journal = {Drug and Alcohol Dependence},

volume = {248},

publisher = {Elsevier BV},

keywords = {Pharmacology, Pharmacology (medical), Psychiatry and Mental health, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37397437,

title = {Kratom withdrawal: Discussions and conclusions of a scientific expert forum},

author = {Jack E Henningfield and Marek C Chawarski and Albert Garcia-Romeu and Oliver Grundmann and Norsyifa Harun and Zurina Hassan and Christopher R McCurdy and Lance R McMahon and Abhisheak Sharma and Mohammed Shoaib and Darshan Singh and Kirsten E Smith and Marc T Swogger and Balasingam Vicknasingam and Zachary Walsh and Daniel W Wang and Marilyn A Huestis},

doi = {10.1016/j.dadr.2023.100142},

issn = {2772-7246},

year  = {2023},

date = {2023-06-01},

journal = {Drug Alcohol Depend Rep},

volume = {7},

pages = {100142},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36912195,

title = {Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis},

author = {Lindsay A Lo and April Christiansen and Lauren Eadie and Justin C Strickland and David D Kim and Michael Boivin and Alasdair M Barr and Caroline A MacCallum},

doi = {10.1111/joim.13627},

issn = {1365-2796},

year  = {2023},

date = {2023-06-01},

journal = {J Intern Med},

volume = {293},

number = {6},

pages = {724--752},

abstract = {BACKGROUND: Findings of liver enzyme elevations in recent cannabidiol studies have raised concerns over liver safety. This study aimed to determine the association between cannabidiol use, liver enzyme elevation, and drug-induced liver injury (DILI).nnMETHODS: In this systematic review and meta-analysis, a search of EMBASE, CENTRAL, CINAHL, Clinicaltrials.gov, Medline, medRxiv, and Web of Science of records up to February 2022 was conducted. Clinical trials initiating daily cannabidiol treatment with serial liver enzyme measures were included. The proportion of liver enzyme elevations and DILI were independently extracted from published reports. Pooled proportions and probability meta-analyses were conducted.nnRESULTS: Cannabidiol use was associated with an increased probability of liver enzyme elevation (N = 12 trials, n = 1229; OR = 5.85 95% CI = 3.84-8.92, p < 0.001) and DILI (N = 12 trials, n = 1229; OR = 4.82 95% CI = 2.46-9.45, p < 0.001) compared to placebo controls. In participants taking cannabidiol (N = 28 trials, n = 1533), the pooled proportion of liver enzyme elevations was 0.074 (95% CI 0.0448-0.1212), and DILI was 0.0296 (95% CI 0.0136-0.0631). High-dose CBD (≥1000 mg/day or ≥20 mg/kg/day) and concomitant antiepileptic drug use were identified as risk factors. No cases were reported in adults using cannabidiol doses <300 mg/day. No cases of severe DILI were reported.nnCONCLUSIONS: Cannabidiol-associated liver enzyme elevations and DILI meet the criteria of common adverse drug events. Clinicians are encouraged to screen for cannabidiol use and monitor liver function in patients at increased risk.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36621047,

title = {Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder},

author = {Jennifer D Ellis and Jamey J Lister and Michael J A Wohl and Mark K Greenwald and David M Ledgerwood},

doi = {10.1016/j.addbeh.2022.107604},

issn = {1873-6327},

year  = {2023},

date = {2023-05-01},

journal = {Addict Behav},

volume = {140},

pages = {107604},

abstract = {BACKGROUND: Depressive symptoms are common in patients seeking medication treatment for opioid use disorder (MOUD treatment) and decrease quality of life but have been inconsistently related to opioid treatment outcomes. Here, we explore whether depressive symptoms may only be related to adverse treatment outcomes among individuals reporting high opioid use-related coping motives (i.e., use of opioids to change affective states) and high trait impulsivity, two common treatment targets.nnMETHODS: Patients seeking MOUD treatment (N = 118) completed several questionnaires within two weeks of their treatment intake. Treatment outcomes (opioid-positive urine screens and days retained in treatment) were extracted from treatment records. Moderation analyses controlling for demographic characteristics and main effects were conducted to explore interaction effects between depressive symptoms and two distinct moderators.nnRESULTS: Depressive symptoms were only related to opioid use during early treatment among patients reporting high opioid use-related coping motives (B = 2.67, p =.004) and patients reporting high trait impulsivity (B = 2.01, p =.039). Further, depressive symptoms were only inversely related to days retained among individuals with high opioid use-related coping motives (B = -10.12, p =.003).nnCONCLUSIONS: Individuals presenting to treatment with opioid-related coping motives and/or impulsivity in the context of depressive symptoms may confer unique risk for adverse treatment outcomes. Clinicians may wish to consider these additive risk factors when developing their treatment plan.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37166910b,

title = {Clinically meaningful individual differences in opioid withdrawal expression},

author = {Orrin D Ware and Kelly E Dunn},

doi = {10.1037/pha0000654},

issn = {1936-2293},

year  = {2023},

date = {2023-05-01},

journal = {Exp Clin Psychopharmacol},

abstract = {Opioid use disorder (OUD) is a significant public health concern. An individual with an OUD may experience withdrawal after stopping opioid use. There has been limited exploration of the individual differences in withdrawal expression. This study expands understanding of this issue by examining the presence and frequency at which persons who have ever had opioid withdrawal have experienced different opioid withdrawal symptoms. Using cross-sectional data captured online from Amazon Mechanical Turk, 124 adults with a lifetime experience of opioid withdrawal were included. Respondents were able to indicate ever experiencing 31 individual opioid withdrawal symptoms. If a symptom was ever experienced, respondents would indicate if it was common and whether it bothered them. A cluster analysis was used to explore variability between the withdrawal symptoms. The sample was primarily men ( = 76, 61.3%) with an average age of 34.7 ( = 11.6). The typical withdrawal syndrome lasted 6.5 days ( = 4.9) and was most severe at 5.7 ( = 4.9) days. Lifetime endorsement of individual symptoms ranged from a high of 73.4% (anxious) to a low of 43.5% (nausea). The cluster analysis was significant, (1, 122) = 215.6,  < .001, with good Bayesian information criteria (0.7). The two clusters are conceptualized here as HIGH ( = 73; 59%) and LOW ( = 51; 41%) endorsing, with a mean of 21.9 and 8.5 items endorsed. These data add to prior studies by suggesting high variability in the individual expression of opioid withdrawal symptoms. It may be time for the field to develop a consensus regarding opioid withdrawal symptom expression and measurement to enhance clinical care. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36473635b,

title = {Correlates and consequences of anxiety and depressive symptom trajectories during early treatment for alcohol use},

author = {Jill A Rabinowitz and Jennifer D Ellis and Jonathan Wells and Justin C Strickland and Brion S Maher and Joseph G Hobelmann and Andrew Huhn},

doi = {10.1016/j.alcohol.2022.11.005},

issn = {1873-6823},

year  = {2023},

date = {2023-05-01},

journal = {Alcohol},

volume = {108},

pages = {44--54},

abstract = {We investigated whether latent trajectories of anxiety and depressive symptoms were associated with clinically relevant variables including treatment attrition among individuals seeking treatment for alcohol use. Participants were drawn from 78 addiction treatment centers and included individuals in treatment for alcohol use, had in-treatment data, and screened positive for anxiety (n = 6147) or depressive symptoms (n = 6197) at intake. Anxiety and depressive symptoms were measured weekly during the first month of treatment. Three trajectories of anxiety symptoms (i.e., Persistent Moderate Anxiety Symptoms, Remitting Moderate Anxiety Symptoms, and Remitting Mild Anxiety Symptoms) and depressive symptoms (i.e., Increasing Moderate Depressive Symptoms, Persistent Moderate Depressive Symptoms, and Remitting Mild Depressive Symptoms) were identified. Women, younger individuals, and individuals who endorsed greater past month benzodiazepine use and depressive symptoms at intake were more likely to be in the Persistent Moderate Anxiety Symptoms trajectory relative to the Remitting Mild Anxiety Symptoms subgroup. Women, individuals who screened positive for anxiety at intake, and individuals reporting past month heroin use were more likely to be in the Increasing Moderate Depressive Symptoms trajectory relative to the Remitting Mild Depressive Symptom trajectory. Trajectories characterized by persistent moderate anxiety and depressive symptoms during the first month of treatment were more likely to drop out of treatment compared to individuals who reported low symptom levels. Findings indicate heterogeneity in the clinical course of anxiety and depressive symptoms among individuals in treatment for alcohol use and highlight that persistently high anxiety and depressive symptoms may pose an impediment to successful treatment completion. Results also demonstrate the importance of considering demographic and clinical characteristics at treatment intake as they may have significant implications for the unfolding of anxiety and depressive symptoms during treatment and subsequent outcomes.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36508168,

title = {Cognitive training and remediation interventions for substance use disorders: a Delphi consensus study},

author = {Antonio Verdejo-Garcia and Tara Rezapour and Emily Giddens and Arash Khojasteh Zonoozi and Parnian Rafei and Jamie Berry and Alfonso Caracuel and Marc L Copersino and Matt Field and Eric L Garland and Valentina Lorenzetti and Leandro Malloy-Diniz and Victoria Manning and Ely M Marceau and David L Pennington and Justin C Strickland and Reinout Wiers and Rahia Fairhead and Alexandra Anderson and Morris Bell and Wouter J Boendermaker and Samantha Brooks and Raimondo Bruno and Salvatore Campanella and Janna Cousijn and W Miles Cox and Andrew C Dean and Karen D Ersche and Ingmar Franken and Brett Froeliger and Pedro Gamito and Thomas E Gladwin and Priscila D Goncalves and Katrijn Houben and Joanna Jacobus and Andrew Jones and Anne M Kaag and Johannes Lindenmeyer and Elly McGrath and Talia Nardo and Jorge Oliveira and Charlotte R Pennington and Kelsey Perrykkad and Hugh Piercy and Claudia I Rupp and Mieke H J Schulte and Lindsay M Squeglia and Petra Staiger and Dan J Stein and Jeff Stein and Maria Stein and William W Stoops and Mary Sweeney and Katie Witkiewitz and Steven P Woods and Richard Yi and Min Zhao and Hamed Ekhtiari},

doi = {10.1111/add.16109},

issn = {1360-0443},

year  = {2023},

date = {2023-05-01},

journal = {Addiction},

volume = {118},

number = {5},

pages = {935--951},

abstract = {AIMS: Substance use disorders (SUD) are associated with cognitive deficits that are not always addressed in current treatments, and this hampers recovery. Cognitive training and remediation interventions are well suited to fill the gap for managing cognitive deficits in SUD. We aimed to reach consensus on recommendations for developing and applying these interventions.nnDESIGN, SETTING AND PARTICIPANTS: We used a Delphi approach with two sequential phases: survey development and iterative surveying of experts. This was an on-line study. During survey development, we engaged a group of 15 experts from a working group of the International Society of Addiction Medicine (Steering Committee). During the surveying process, we engaged a larger pool of experts (n = 54) identified via recommendations from the Steering Committee and a systematic review.nnMEASUREMENTS: Survey with 67 items covering four key areas of intervention development: targets, intervention approaches, active ingredients and modes of delivery.nnFINDINGS: Across two iterative rounds (98% retention rate), the experts reached a consensus on 50 items including: (i) implicit biases, positive affect, arousal, executive functions and social processing as key targets of interventions; (ii) cognitive bias modification, contingency management, emotion regulation training and cognitive remediation as preferred approaches; (iii) practice, feedback, difficulty-titration, bias modification, goal-setting, strategy learning and meta-awareness as active ingredients; and (iv) both addiction treatment work-force and specialized neuropsychologists facilitating delivery, together with novel digital-based delivery modalities.nnCONCLUSIONS: Expert recommendations on cognitive training and remediation for substance use disorders highlight the relevance of targeting implicit biases, reward, emotion regulation and higher-order cognitive skills via well-validated intervention approaches qualified with mechanistic techniques and flexible delivery options.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36473635,

title = {Correlates and consequences of anxiety and depressive symptom trajectories during early treatment for alcohol use},

author = {Jill A Rabinowitz and Jennifer D Ellis and Jonathan Wells and Justin C Strickland and Brion S Maher and Joseph G Hobelmann and Andrew Huhn},

doi = {10.1016/j.alcohol.2022.11.005},

issn = {1873-6823},

year  = {2023},

date = {2023-05-01},

journal = {Alcohol},

volume = {108},

pages = {44--54},

abstract = {We investigated whether latent trajectories of anxiety and depressive symptoms were associated with clinically relevant variables including treatment attrition among individuals seeking treatment for alcohol use. Participants were drawn from 78 addiction treatment centers and included individuals in treatment for alcohol use, had in-treatment data, and screened positive for anxiety (n = 6147) or depressive symptoms (n = 6197) at intake. Anxiety and depressive symptoms were measured weekly during the first month of treatment. Three trajectories of anxiety symptoms (i.e., Persistent Moderate Anxiety Symptoms, Remitting Moderate Anxiety Symptoms, and Remitting Mild Anxiety Symptoms) and depressive symptoms (i.e., Increasing Moderate Depressive Symptoms, Persistent Moderate Depressive Symptoms, and Remitting Mild Depressive Symptoms) were identified. Women, younger individuals, and individuals who endorsed greater past month benzodiazepine use and depressive symptoms at intake were more likely to be in the Persistent Moderate Anxiety Symptoms trajectory relative to the Remitting Mild Anxiety Symptoms subgroup. Women, individuals who screened positive for anxiety at intake, and individuals reporting past month heroin use were more likely to be in the Increasing Moderate Depressive Symptoms trajectory relative to the Remitting Mild Depressive Symptom trajectory. Trajectories characterized by persistent moderate anxiety and depressive symptoms during the first month of treatment were more likely to drop out of treatment compared to individuals who reported low symptom levels. Findings indicate heterogeneity in the clinical course of anxiety and depressive symptoms among individuals in treatment for alcohol use and highlight that persistently high anxiety and depressive symptoms may pose an impediment to successful treatment completion. Results also demonstrate the importance of considering demographic and clinical characteristics at treatment intake as they may have significant implications for the unfolding of anxiety and depressive symptoms during treatment and subsequent outcomes.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37195789b,

title = {Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl},

author = {H Elizabeth Bird and Andrew S Huhn and Kelly E Dunn},

doi = {10.1097/ADM.0000000000001185},

issn = {1935-3227},

year  = {2023},

date = {2023-05-01},

journal = {J Addict Med},

abstract = {OBJECTIVES: This narrative review summarizes literature on pharmaceutical fentanyl's absorption, distribution, metabolism, and excretion patterns to inform research on illicitly manufactured fentanyl (IMF).nnRESULTS: Fentanyl is highly lipophilic, lending itself to rapid absorption by highly perfused tissues (including the brain) before redistributing from these tissues to muscle and fat. Fentanyl is eliminated primarily by metabolism and urinary excretion of metabolites (norfentanyl and other minor metabolites). Fentanyl has a long terminal elimination, with a documented secondary peaking phenomenon that can manifest as "fentanyl rebound." Clinical implications in overdose (respiratory depression, muscle rigidity, and "wooden chest syndrome") and opioid use disorder treatment (subjective effects, withdrawal, and buprenorphine-precipitated withdrawal) are discussed. The authors highlight research gaps derived from differences in medicinal fentanyl studies and IMF use patterns, including that medicinal fentanyl studies are largely conducted with persons who were opioid-naive, anesthetized, or had severe chronic pain and that IMF use is characterized by supratherapeutic doses and frequent and sustained administration patterns, as well as adulteration with other substances and/or fentanyl analogs.nnCONCLUSIONS: This review reexamines information yielded from decades of medicinal fentanyl research and applies elements of the pharmacokinetic profile to persons with IMF exposure. In persons who use drugs, peripheral accumulation of fentanyl may be leading to prolonged exposure. More focused research on the pharmacology of fentanyl in persons using IMF is warranted.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37166910,

title = {Clinically meaningful individual differences in opioid withdrawal expression},

author = {Orrin D Ware and Kelly E Dunn},

doi = {10.1037/pha0000654},

issn = {1936-2293},

year  = {2023},

date = {2023-05-01},

journal = {Exp Clin Psychopharmacol},

abstract = {Opioid use disorder (OUD) is a significant public health concern. An individual with an OUD may experience withdrawal after stopping opioid use. There has been limited exploration of the individual differences in withdrawal expression. This study expands understanding of this issue by examining the presence and frequency at which persons who have ever had opioid withdrawal have experienced different opioid withdrawal symptoms. Using cross-sectional data captured online from Amazon Mechanical Turk, 124 adults with a lifetime experience of opioid withdrawal were included. Respondents were able to indicate ever experiencing 31 individual opioid withdrawal symptoms. If a symptom was ever experienced, respondents would indicate if it was common and whether it bothered them. A cluster analysis was used to explore variability between the withdrawal symptoms. The sample was primarily men ( = 76, 61.3%) with an average age of 34.7 ( = 11.6). The typical withdrawal syndrome lasted 6.5 days ( = 4.9) and was most severe at 5.7 ( = 4.9) days. Lifetime endorsement of individual symptoms ranged from a high of 73.4% (anxious) to a low of 43.5% (nausea). The cluster analysis was significant, (1, 122) = 215.6,  < .001, with good Bayesian information criteria (0.7). The two clusters are conceptualized here as HIGH ( = 73; 59%) and LOW ( = 51; 41%) endorsing, with a mean of 21.9 and 8.5 items endorsed. These data add to prior studies by suggesting high variability in the individual expression of opioid withdrawal symptoms. It may be time for the field to develop a consensus regarding opioid withdrawal symptom expression and measurement to enhance clinical care. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37195789,

title = {Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl},

author = {H Elizabeth Bird and Andrew S Huhn and Kelly E Dunn},

doi = {10.1097/ADM.0000000000001185},

issn = {1935-3227},

year  = {2023},

date = {2023-05-01},

journal = {J Addict Med},

abstract = {OBJECTIVES: This narrative review summarizes literature on pharmaceutical fentanyl's absorption, distribution, metabolism, and excretion patterns to inform research on illicitly manufactured fentanyl (IMF).nnRESULTS: Fentanyl is highly lipophilic, lending itself to rapid absorption by highly perfused tissues (including the brain) before redistributing from these tissues to muscle and fat. Fentanyl is eliminated primarily by metabolism and urinary excretion of metabolites (norfentanyl and other minor metabolites). Fentanyl has a long terminal elimination, with a documented secondary peaking phenomenon that can manifest as "fentanyl rebound." Clinical implications in overdose (respiratory depression, muscle rigidity, and "wooden chest syndrome") and opioid use disorder treatment (subjective effects, withdrawal, and buprenorphine-precipitated withdrawal) are discussed. The authors highlight research gaps derived from differences in medicinal fentanyl studies and IMF use patterns, including that medicinal fentanyl studies are largely conducted with persons who were opioid-naive, anesthetized, or had severe chronic pain and that IMF use is characterized by supratherapeutic doses and frequent and sustained administration patterns, as well as adulteration with other substances and/or fentanyl analogs.nnCONCLUSIONS: This review reexamines information yielded from decades of medicinal fentanyl research and applies elements of the pharmacokinetic profile to persons with IMF exposure. In persons who use drugs, peripheral accumulation of fentanyl may be leading to prolonged exposure. More focused research on the pharmacology of fentanyl in persons using IMF is warranted.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rabinowitz2023b,

title = {Correlates and consequences of anxiety and depressive symptom trajectories during early treatment for alcohol use},

author = {Jill A. Rabinowitz and Jennifer D. Ellis and Jonathan Wells and Justin C. Strickland and Brion S. Maher and Joseph G. Hobelmann and Andrew Huhn},

doi = {10.1016/j.alcohol.2022.11.005},

issn = {0741-8329},

year  = {2023},

date = {2023-05-00},

journal = {Alcohol},

volume = {108},

pages = {44--54},

publisher = {Elsevier BV},

keywords = {Behavioral Neuroscience, Biochemistry, General Medicine, Health (social science), Neurology, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023d,

title = {Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder},

author = {Jennifer D. Ellis and Jamey J. Lister and Michael J.A. Wohl and Mark K. Greenwald and David M. Ledgerwood},

doi = {10.1016/j.addbeh.2022.107604},

issn = {0306-4603},

year  = {2023},

date = {2023-05-00},

journal = {Addictive Behaviors},

volume = {140},

publisher = {Elsevier BV},

keywords = {Clinical Psychology, Medicine (miscellaneous), Psychiatry and Mental health, Toxicology},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36871377,

title = {Oral Cannabidiol does not alter Alcohol Seeking and Self-Administration in Baboons},

author = {Catherine F Moore and C Austin Zamarripa and Elise M Weerts},

doi = {10.1016/j.drugalcdep.2023.109829},

issn = {1879-0046},

year  = {2023},

date = {2023-04-01},

journal = {Drug Alcohol Depend},

volume = {245},

pages = {109829},

abstract = {BACKGROUND: The cannabinoid cannabidiol (CBD) is currently under investigation as a pharmacotherapy for alcohol use disorder. The aim of the present study was to examine whether acute and chronic treatment with pure CBD would decrease alcohol seeking and consumption behaviors or alter drinking patterns in male baboons with extensive histories of daily alcohol intake (1 g/kg/day).nnMETHODS: Seven male baboons self-administered oral alcohol (4% w/v) in a validated chained schedule of reinforcement (CSR) procedure that modeled periods of anticipation, seeking, and consumption. In Experiment 1, CBD (5-40 mg/kg) or vehicle (peanut oil, USP) was administered orally 15- or 90-minutes prior to the start of the session. In Experiment 2, oral doses of CBD (10-40 mg/kg) or vehicle were administered for 5 consecutive days during ongoing alcohol access under the CSR. In addition, behavioral observations were conducted to assess potential drug side effects (e.g., sedation, motor incoordination) following chronic CBD treatment immediately after the session and 24-hours after drug administration.nnRESULTS: Across both experiments, baboons self-administered an average of 1 g/kg/day of alcohol under baseline conditions. Administration of acute or chronic CBD (150-1200 mg total CBD dose/day) that encompassed the purported therapeutic dose range did not significantly reduce alcohol seeking, self-administration or intake (g/kg). Drinking patterns (i.e., number of drinks/bouts, bout duration, nor interdrink interval) also were not altered. There were no observable behavioral disruptions following CBD treatment.nnCONCLUSIONS: In sum, the current data do not support use of pure CBD as an effective pharmacotherapy to reduce ongoing excessive drinking.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36871378b,

title = {A cross-sectional survey on cannabis: Characterizing motives, opinions, and subjective experiences associated with the use of various oral cannabis products},

author = {Ashley N Dowd and C Austin Zamarripa and Dennis J Sholler and Justin C Strickland and Elia Goffi and Jacob T Borodovsky and Elise M Weerts and Ryan Vandrey and Tory R Spindle},

doi = {10.1016/j.drugalcdep.2023.109826},

issn = {1879-0046},

year  = {2023},

date = {2023-04-01},

journal = {Drug Alcohol Depend},

volume = {245},

pages = {109826},

abstract = {BACKGROUND: Cannabis-infused products available for oral consumption include food and drink items (i.e., edibles) (e.g., baked goods, gummy-, chocolate-, and hard-candies, beverages/drinks) as well as non-food formulations (e.g., oils/tinctures, pills/capsules). This study characterized the motives, opinions, and subjective experiences associated with the use of these seven subtypes of oral cannabis products.nnMETHODS: This web-based survey collected cross-sectional, self-report data from a convenience sample of 370 adults regarding various use-motives, self-reported cannabinoid content, subjective experiences, and opinions related to ingesting oral cannabis products with alcohol and/or food. Advice participants had received about modifying oral cannabis product effects, in general, was also collected.nnRESULTS: Participants reported consuming cannabis baked goods and gummy candies most frequently over the past year (68% and 63%, respectively). Participants were less likely to use oils/tinctures for enjoyment/desire relative to other product types and more likely to use oils/tinctures for therapeutic purposes (e.g., medication-replacement). Self-reported cannabinoid content was highly variable across participants and within product subtype. Participants reported feeling stronger and longer-lasting effects when consuming oral cannabis products on an empty stomach and 43% received advice to "eat a snack or meal" to mitigate effects that are too strong, which contrasts with controlled studies. Finally, 43% of participants reported modifying their experiences with alcohol at least some of time.nnCONCLUSIONS: These findings underscore the need to further evaluate use-motives as well as the interaction between dietary factors, cannabinoid pharmacokinetics, and subjective drug effects and the interactive effects of oral cannabis products and alcohol in a controlled laboratory setting.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid37041624,

title = {Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors},

author = {Katherine Hill and Stephen Gibson and Oliver Grundmann and Kirsten E Smith and Jonathan Ballard and Corneliu N Stanciu},

doi = {10.1186/s13011-023-00531-4},

issn = {1747-597X},

year  = {2023},

date = {2023-04-01},

journal = {Subst Abuse Treat Prev Policy},

volume = {18},

number = {1},

pages = {21},

abstract = {BACKGROUND: "Kratom" commonly refers to the botanical Mitragyna speciosa, native to Southeast Asia, which is increasingly used globally for its unique pharmacological effects. Motives for using the whole plant material or kratom-derived products include self-management of pain, mental health disorders, symptoms related to substance use disorders, and/or to increase energy. In the United States, kratom products have varying alkaloid content, potencies, and marketing profiles. There is little regulatory oversight over kratom, as it is currently not approved as a dietary supplement by the Food and Drug Administration. This results in substantial variability in labeling of kratom products and the product information provided to consumers.nnMETHODS: In January 2023, we evaluated the American Kratom Association's Good Manufacturing Practices (GMP) qualified vendors' websites (n = 42) using the well-established and validated DISCERN instrument to examine the quality of health information provided to consumers. DISCERN contains 15 five-point Likert-scale questions on specific criteria, with the highest possible score being 75, indicating that all the DISCERN criteria have been fulfilled by the website (i.e., the highest quality information is provided to consumers).nnRESULTS: The mean DISCERN score for all evaluated online kratom vendors was 32.72 (SD = 6.69; score range 18.00-43.76). Overall, vendors scored higher on DISCERN questions assessing the website's reliability, as vendors typically provided clear information for consumers about product availability, purchasing, shipping, etc. On average, vendors scored poorly on the DISCERN section pertaining to the quality of the health information provided. Information on kratom's potential risks and benefits was particularly insufficient.nnCONCLUSIONS: Consumers require high quality information in order to make informed decisions concerning use, which entails disclosure of known risks and potential benefits. The online kratom vendors evaluated in this study should consider enhancing the quality of health information provided, especially information regarding kratom's risks and benefits. Further, consumers should be made aware of current knowledge gaps related to kratom's effects. Clinicians must also be aware of the lack of evidence-based information available to their patients who use kratom or are interested in using kratom products, in order to facilitate educational discussions with them.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36871378,

title = {A cross-sectional survey on cannabis: Characterizing motives, opinions, and subjective experiences associated with the use of various oral cannabis products},

author = {Ashley N Dowd and C Austin Zamarripa and Dennis J Sholler and Justin C Strickland and Elia Goffi and Jacob T Borodovsky and Elise M Weerts and Ryan Vandrey and Tory R Spindle},

doi = {10.1016/j.drugalcdep.2023.109826},

issn = {1879-0046},

year  = {2023},

date = {2023-04-01},

journal = {Drug Alcohol Depend},

volume = {245},

pages = {109826},

abstract = {BACKGROUND: Cannabis-infused products available for oral consumption include food and drink items (i.e., edibles) (e.g., baked goods, gummy-, chocolate-, and hard-candies, beverages/drinks) as well as non-food formulations (e.g., oils/tinctures, pills/capsules). This study characterized the motives, opinions, and subjective experiences associated with the use of these seven subtypes of oral cannabis products.nnMETHODS: This web-based survey collected cross-sectional, self-report data from a convenience sample of 370 adults regarding various use-motives, self-reported cannabinoid content, subjective experiences, and opinions related to ingesting oral cannabis products with alcohol and/or food. Advice participants had received about modifying oral cannabis product effects, in general, was also collected.nnRESULTS: Participants reported consuming cannabis baked goods and gummy candies most frequently over the past year (68% and 63%, respectively). Participants were less likely to use oils/tinctures for enjoyment/desire relative to other product types and more likely to use oils/tinctures for therapeutic purposes (e.g., medication-replacement). Self-reported cannabinoid content was highly variable across participants and within product subtype. Participants reported feeling stronger and longer-lasting effects when consuming oral cannabis products on an empty stomach and 43% received advice to "eat a snack or meal" to mitigate effects that are too strong, which contrasts with controlled studies. Finally, 43% of participants reported modifying their experiences with alcohol at least some of time.nnCONCLUSIONS: These findings underscore the need to further evaluate use-motives as well as the interaction between dietary factors, cannabinoid pharmacokinetics, and subjective drug effects and the interactive effects of oral cannabis products and alcohol in a controlled laboratory setting.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35467921b,

title = {A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol},

author = {Cecilia L Bergeria and Justin C Strickland and Tory R Spindle and Maja Kalaba and Prem Umang Satyavolu and Matthew Feldner and Ryan Vandrey and Marcel Bonn-Miller and Erica N Peters and Elise Weerts},

doi = {10.1037/pha0000565},

issn = {1936-2293},

year  = {2023},

date = {2023-04-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {2},

pages = {312--317},

abstract = {Delta-8-tetrahydrocannabinol (Δ8-THC) has emerged as a new retail cannabinoid product in the U.S. This study queried Δ8-THC users about product use characteristics and self-reported drug effects. Participants were recruited via a large online crowdsourcing platform (Amazon Mechanical Turk). Adults ( = 252) with past year Δ8-THC use (35% with at least weekly use) completed surveys and open-ended questions related to their reasons for using and past experiences with Δ8-THC-containing retail products. Participants with past year use of Δ9-tetrahydrocannabinol (Δ9-THC) and/or cannabidiol (CBD; 81% and 63%) compared the effects of Δ8-THC to those of Δ9-THC and/or CBD by rating drug effects on a visual analog scale from -50 to + 50 where negative scores indicated Δ8-THC effects are weaker, positive scores indicated Δ8-THC effects are stronger, and a score of 0 indicated equal effects to Δ9-THC or CBD. Compared to Δ9-THC, self-reported ratings for "Drug effect," "Bad effect," "Sick," "Anxiety," "Paranoia," "Irritability," "Restlessness," "Memory Problems," and "Trouble Performing Routine Tasks" were lower for Δ8-THC ( = -0.21 to -0.44). Compared to CBD, ratings for Δ8-THC effects were higher for "Drug effect," "Good effect," "High," "Relaxed," "Sleepy," "Hunger/Have the Munchies," "Memory Problems," "Trouble Performing Routine Tasks," and "Paranoia" ( = 0.27-1.02). Qualitative responses indicated that participants used Δ8-THC because it is perceived as (a) legal, (b) a substitute or similar to Δ9-THC, and/or (c) less intense than Δ9-THC. Δ8-THC is an understudied psychoactive component of cannabis that shares more characteristics with Δ9-THC than CBD and should be characterized further with human laboratory studies. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35467921,

title = {A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol},

author = {Cecilia L Bergeria and Justin C Strickland and Tory R Spindle and Maja Kalaba and Prem Umang Satyavolu and Matthew Feldner and Ryan Vandrey and Marcel Bonn-Miller and Erica N Peters and Elise Weerts},

doi = {10.1037/pha0000565},

issn = {1936-2293},

year  = {2023},

date = {2023-04-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {2},

pages = {312--317},

abstract = {Delta-8-tetrahydrocannabinol (Δ8-THC) has emerged as a new retail cannabinoid product in the U.S. This study queried Δ8-THC users about product use characteristics and self-reported drug effects. Participants were recruited via a large online crowdsourcing platform (Amazon Mechanical Turk). Adults ( = 252) with past year Δ8-THC use (35% with at least weekly use) completed surveys and open-ended questions related to their reasons for using and past experiences with Δ8-THC-containing retail products. Participants with past year use of Δ9-tetrahydrocannabinol (Δ9-THC) and/or cannabidiol (CBD; 81% and 63%) compared the effects of Δ8-THC to those of Δ9-THC and/or CBD by rating drug effects on a visual analog scale from -50 to + 50 where negative scores indicated Δ8-THC effects are weaker, positive scores indicated Δ8-THC effects are stronger, and a score of 0 indicated equal effects to Δ9-THC or CBD. Compared to Δ9-THC, self-reported ratings for "Drug effect," "Bad effect," "Sick," "Anxiety," "Paranoia," "Irritability," "Restlessness," "Memory Problems," and "Trouble Performing Routine Tasks" were lower for Δ8-THC ( = -0.21 to -0.44). Compared to CBD, ratings for Δ8-THC effects were higher for "Drug effect," "Good effect," "High," "Relaxed," "Sleepy," "Hunger/Have the Munchies," "Memory Problems," "Trouble Performing Routine Tasks," and "Paranoia" ( = 0.27-1.02). Qualitative responses indicated that participants used Δ8-THC because it is perceived as (a) legal, (b) a substitute or similar to Δ9-THC, and/or (c) less intense than Δ9-THC. Δ8-THC is an understudied psychoactive component of cannabis that shares more characteristics with Δ9-THC than CBD and should be characterized further with human laboratory studies. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36977804,

title = {Correlates of illness uncertainty in cancer survivors and family caregivers: a systematic review and meta-analysis},

author = {Ting Guan and Mimi V Chapman and Lisa de Saxe Zerden and Anjalee Sharma and Ding-Geng Chen and Lixin Song},

doi = {10.1007/s00520-023-07705-7},

issn = {1433-7339},

year  = {2023},

date = {2023-03-01},

journal = {Support Care Cancer},

volume = {31},

number = {4},

pages = {242},

abstract = {PURPOSE: Illness uncertainty is widely recognized as a psychosocial stressor for cancer survivors and their family caregivers. This systematic review and meta-analysis aimed to identify the sociodemographic, physical, and psychosocial correlates that are associated with illness uncertainty in adult cancer survivors and their family caregivers.nnMETHODS: Six scholarly databases were searched. Data synthesis was based on Mishel's Uncertainty in Illness Theory. Person's r was used as the effect size metric in the meta-analysis. Risk of bias was assessed using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.nnRESULTS: Of 1116 articles, 21 articles met the inclusion criteria. Of 21 reviewed studies, 18 focused on cancer survivors, one focused on family caregivers, and 2 included survivors and family caregivers. Findings identified distinct correlates for illness uncertainty in cancer survivors, including sociodemographic factors (e.g., age, gender, race), stimuli frame (e.g., symptom, family history of cancer), structure providers (e.g., education), coping, and adaptation. Notable effect sizes were observed in the correlations between illness uncertainty and social support, quality of life, depression, and anxiety. Caregivers' illness uncertainty was associated with their race, general health, perception of influence, social support, quality of life, and survivors' prostate-specific antigen levels. Insufficient data precluded examining effect size of correlates of illness uncertainty among family caregivers.nnCONCLUSION: This is the first systematic review and meta-analysis to summarize the literature on illness uncertainty among adult cancer survivors and family caregivers. Findings contribute to the growing literature on managing illness uncertainty among cancer survivors and family caregivers.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36880895c,

title = {Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study},

author = {Jennifer D Ellis and Jill A Rabinowitz and Orrin D Ware and Jonathan Wells and Kelly E Dunn and Andrew S Huhn},

doi = {10.1016/j.josat.2022.208932},

issn = {2949-8759},

year  = {2023},

date = {2023-03-01},

journal = {J Subst Use Addict Treat},

volume = {146},

pages = {208932},

abstract = {INTRODUCTION: Polysubstance use is common among individuals seeking treatment for substance use disorders (SUD). However, we know less about patterns and correlates of polysubstance use among treatment-seeking populations. The current study aimed to identify latent patterns of polysubstance use and associated risk factors in persons entering SUD treatment.nnMETHODS: Patients (N = 28,526) being admitted for substance use treatment reported on their use of thirteen substances (e.g., alcohol, cannabis, cocaine, amphetamines, methamphetamines, other stimulants, heroin, other opioids, benzodiazepines, inhalants, synthetics, hallucinogens, and club drugs) in the month before treatment and prior to the month before treatment. Latent class analysis (LCA) determined the relationship between class membership and gender, age, employment status, unstable housing, self-harm, overdose, past treatment, depression, generalized anxiety disorder, and/or post-traumatic stress disorder (PTSD).nnRESULTS: Identified classes included: 1) Alcohol primary, 2) Moderate probability of past-month alcohol, cannabis, and/or opioid use; 3) Alcohol primary, Lifetime cannabis and cocaine use; 4) Opioid primary, Lifetime use of alcohol, cannabis, hallucinogens, club drugs, amphetamines, and cocaine; 5) Moderate probability of past-month alcohol, cannabis, and/or opioid use, Lifetime use of various substances; 6) Alcohol and cannabis primary, Lifetime use of various substances; and 7) High past-month polysubstance use. Individuals who engaged in past-month polysubstance use attended to face elevated risk of screening positive for recent unstable housing, unemployment, depression, anxiety, PTSD, self-harm, and overdose.nnCONCLUSIONS: Current polysubstance use is associated with significant clinical complexity. Tailored treatments that reduce harms resulting from polysubstance use and related psychiatric comorbidity may improve treatment outcomes in this population.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36710645,

title = {Reinforcer pathology, probabilistic choice, and medication adherence in patients with multiple sclerosis},

author = {David P Jarmolowicz and Tadd D Schneider and Justin C Strickland and Amanda S Bruce and Derek D Reed and Jared M Bruce},

doi = {10.1002/jeab.830},

issn = {1938-3711},

year  = {2023},

date = {2023-03-01},

journal = {J Exp Anal Behav},

volume = {119},

number = {2},

pages = {275--285},

abstract = {The reinforcer pathology model posits that core behavioral economic mechanisms, including delay discounting and behavioral economic demand, underlie adverse health decisions and related clinical disorders. Extensions beyond substance use disorder and obesity, however, are limited. Using a reinforcer pathology framework, this study evaluates medical adherence decisions in patients with multiple sclerosis. Participants completed behavioral economic measures, including delay discounting, probability discounting, and a medication purchase task. A medical decision-making task was also used to evaluate how sensitivity to mild side effect risk and efficacy contributed to the likelihood of taking a hypothetical disease-modifying therapy. Less steep delay discounting and more intense (greater) medication demand were independently associated with greater adherence to the medication decision-making procedure. More generally, the pattern of interrelations between the medication-specific and general behavioral economic metrics was consistent with and contributes to the reinforcer pathology model. Additional research is warranted to expand these models to different populations and health behaviors, including those of a positive health orientation (i.e., medication adherence).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36880895b,

title = {Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study},

author = {Jennifer D Ellis and Jill A Rabinowitz and Orrin D Ware and Jonathan Wells and Kelly E Dunn and Andrew S Huhn},

doi = {10.1016/j.josat.2022.208932},

issn = {2949-8759},

year  = {2023},

date = {2023-03-01},

journal = {J Subst Use Addict Treat},

volume = {146},

pages = {208932},

abstract = {INTRODUCTION: Polysubstance use is common among individuals seeking treatment for substance use disorders (SUD). However, we know less about patterns and correlates of polysubstance use among treatment-seeking populations. The current study aimed to identify latent patterns of polysubstance use and associated risk factors in persons entering SUD treatment.nnMETHODS: Patients (N = 28,526) being admitted for substance use treatment reported on their use of thirteen substances (e.g., alcohol, cannabis, cocaine, amphetamines, methamphetamines, other stimulants, heroin, other opioids, benzodiazepines, inhalants, synthetics, hallucinogens, and club drugs) in the month before treatment and prior to the month before treatment. Latent class analysis (LCA) determined the relationship between class membership and gender, age, employment status, unstable housing, self-harm, overdose, past treatment, depression, generalized anxiety disorder, and/or post-traumatic stress disorder (PTSD).nnRESULTS: Identified classes included: 1) Alcohol primary, 2) Moderate probability of past-month alcohol, cannabis, and/or opioid use; 3) Alcohol primary, Lifetime cannabis and cocaine use; 4) Opioid primary, Lifetime use of alcohol, cannabis, hallucinogens, club drugs, amphetamines, and cocaine; 5) Moderate probability of past-month alcohol, cannabis, and/or opioid use, Lifetime use of various substances; 6) Alcohol and cannabis primary, Lifetime use of various substances; and 7) High past-month polysubstance use. Individuals who engaged in past-month polysubstance use attended to face elevated risk of screening positive for recent unstable housing, unemployment, depression, anxiety, PTSD, self-harm, and overdose.nnCONCLUSIONS: Current polysubstance use is associated with significant clinical complexity. Tailored treatments that reduce harms resulting from polysubstance use and related psychiatric comorbidity may improve treatment outcomes in this population.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36880895,

title = {Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study},

author = {Jennifer D Ellis and Jill A Rabinowitz and Orrin D Ware and Jonathan Wells and Kelly E Dunn and Andrew S Huhn},

doi = {10.1016/j.josat.2022.208932},

issn = {2949-8759},

year  = {2023},

date = {2023-03-01},

journal = {J Subst Use Addict Treat},

volume = {146},

pages = {208932},

abstract = {INTRODUCTION: Polysubstance use is common among individuals seeking treatment for substance use disorders (SUD). However, we know less about patterns and correlates of polysubstance use among treatment-seeking populations. The current study aimed to identify latent patterns of polysubstance use and associated risk factors in persons entering SUD treatment.nnMETHODS: Patients (N = 28,526) being admitted for substance use treatment reported on their use of thirteen substances (e.g., alcohol, cannabis, cocaine, amphetamines, methamphetamines, other stimulants, heroin, other opioids, benzodiazepines, inhalants, synthetics, hallucinogens, and club drugs) in the month before treatment and prior to the month before treatment. Latent class analysis (LCA) determined the relationship between class membership and gender, age, employment status, unstable housing, self-harm, overdose, past treatment, depression, generalized anxiety disorder, and/or post-traumatic stress disorder (PTSD).nnRESULTS: Identified classes included: 1) Alcohol primary, 2) Moderate probability of past-month alcohol, cannabis, and/or opioid use; 3) Alcohol primary, Lifetime cannabis and cocaine use; 4) Opioid primary, Lifetime use of alcohol, cannabis, hallucinogens, club drugs, amphetamines, and cocaine; 5) Moderate probability of past-month alcohol, cannabis, and/or opioid use, Lifetime use of various substances; 6) Alcohol and cannabis primary, Lifetime use of various substances; and 7) High past-month polysubstance use. Individuals who engaged in past-month polysubstance use attended to face elevated risk of screening positive for recent unstable housing, unemployment, depression, anxiety, PTSD, self-harm, and overdose.nnCONCLUSIONS: Current polysubstance use is associated with significant clinical complexity. Tailored treatments that reduce harms resulting from polysubstance use and related psychiatric comorbidity may improve treatment outcomes in this population.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36920397,

title = {Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial},

author = {Orrin D Ware and Mary M Sweeney and Colin Cunningham and Annie Umbricht and Maxine Stitzer and Kelly E Dunn},

doi = {10.1001/jamanetworkopen.2023.2278},

issn = {2574-3805},

year  = {2023},

date = {2023-03-01},

journal = {JAMA Netw Open},

volume = {6},

number = {3},

pages = {e232278},

abstract = {IMPORTANCE: Opioid-stimulant co-use is a common problem with few evidence-based treatments.nnOBJECTIVE: To examine bupropion slow release (SR) enhancement of a tailored abstinence incentive program for stimulant use in persons with opioid use disorder.nnDESIGN, SETTING, AND PARTICIPANTS: This 26-week, double-blind, placebo-controlled randomized clinical trial with a 4-week follow-up period was conducted at 4 methadone treatment programs in Baltimore, Maryland. Included participants were persons receiving methadone for the treatment of opioid use disorder with past 3-month cocaine use and current cocaine use disorder between March 2015 and September 2019. Data were analyzed from November 2020 through August 2022.nnINTERVENTIONS: A 6-week incentive induction period with monetary incentives for evidence of cocaine abstinence during thrice-weekly urine testing was conducted. Persons achieving 2 weeks of consecutive abstinence during induction were assigned to the relapse prevention group (20 individuals); otherwise, individuals were assigned to the abstinence initiation group (60 individuals). Participants were randomized within incentive groups to bupropion SR (150 mg oral twice daily; 40 participants) or placebo (40 participants). Incentives were available until week 26, and study medication ended week 30.nnMAIN OUTCOMES AND MEASURES: The mean percentage of participants with cocaine abstinence (by negative urinalysis or self-report) during weeks 7 to 26 (ie, the incentive intervention period) and 27 to 30 (ie, the follow-up period) and the percentage of participants testing negative for cocaine at weeks 26 and 30 were assessed. Main effects of medication collapsed across incentive conditions and sensitivity analyses of medications within incentive conditions were assessed. Analyses were conducted in the modified intention-to-treat sample (ie, 80 individuals who received ≥1 dose of study medication) and completers (ie, 52 individuals who completed ≥1 visit during week 30).nnRESULTS: Among 80 participants (42 Black [52.5% ] and 35 White [43.8%]; mean [SD] age, 45.7 (9.4) years; 52 males [65.0%]) receiving methadone for opioid use disorder, 40 participants were randomized to receive bupropion SR and 40 participants to receive placebo. No significant difference on urinalysis or self-reported cocaine use was observed between medication groups. Sensitivity analyses revealed differential patterns for incentive subgroups. Participants in the relapse prevention group had high abstinence (>80%; eg, during weeks 7-26 in the modified intention-to-treat analysis, 410 of 456 samples [89.9%] from participants in the bupropion SR group tested negative for cocaine) throughout the trial regardless of whether they were randomized to bupropion SR or placebo. Participants in the abstinence initiation group had better outcomes with bupropion SR than placebo throughout the trial (mean [SD] total number of samples testing negative for cocaine, 30.3 [21.6] samples for bupropion SR vs 17.1 [14.9] samples for placebo; P = .05) and more participants receiving bupropion SR than placebo were abstinent at the end of the study (20 of 30 participants [66.7%] vs 9 of 30 participants [30.0%]; P = .04).nnCONCLUSIONS AND RELEVANCE: In this randomized clinical trial, an overall benefit for bupropion SR vs placebo when combined with a financial abstinence incentive program was not observed. Results among incentive subgroups suggest that continued evaluation of medications, including bupropion SR, for stimulant treatment using a tailored approach that factors early abstinence into study design and interpretation may be needed.nnTRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02111798.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36920881,

title = {Iteration is not solving the opioid crisis, it's time for transformation},

author = {Kelly E Dunn},

doi = {10.1080/00952990.2023.2170807},

issn = {1097-9891},

year  = {2023},

date = {2023-03-01},

journal = {Am J Drug Alcohol Abuse},

volume = {49},

number = {2},

pages = {151--158},

abstract = {Opioid use disorder (OUD) produces exceedingly high rates of morbidity and mortality in the United States and throughout the world. Almost 90% of persons qualifying for treatment do not enter treatment and 72% of those who initiate treatment leave within 60 days. This Perspective posits that over the past decade our OUD treatment system has produced only small iterative gains in treatment access because, in part, it is founded in a series of top-down regulatory policies dating back more than 100 years. These policies prioritized restricting persons with OUD from having access to opioid agonists over empirical discovery of treatment best practice. It further suggests that for persons who are not already responding positively to our existing treatments, we may need to fundamentally transform care to enact true, meaningful change. Four potential considerations are outlined: expanding beyond long-acting opioids for treatment, embracing safe use as a viable therapeutic target, ending closed medication distribution systems, and partnering with our patients. The overarching aim of this discussion is to motivate broader thinking about new solutions for the patients for whom the existing strategies are not working and who may benefit from more transformative approaches. Though efforts to-date to expand existing treatment systems and find new ways to promote existing MOUDs have been important, these efforts have represented iterative changes. For us to meet our goal of substantially reducing opioid-related harms, it may be time to consider strategies that represent true transformation.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ellis2023,

title = {Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study},

author = {Jennifer D. Ellis and Jill A. Rabinowitz and Orrin D. Ware and Jonathan Wells and Kelly E. Dunn and Andrew S. Huhn},

doi = {10.1016/j.josat.2022.208932},

issn = {2949-8759},

year  = {2023},

date = {2023-03-00},

journal = {Journal of Substance Use and Addiction Treatment},

volume = {146},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36495737,

title = {Culturally sensitive prevention programs for substance use among adolescents of color: A systematic review and meta-analysis of randomized controlled trials},

author = {Ai Bo and Trenette Clark Goings and Caroline B R Evans and Anjalee Sharma and Zoe Jennings and Brenna Durand and Angela Bardeen and Andrea Murray-Lichtman},

doi = {10.1016/j.cpr.2022.102233},

issn = {1873-7811},

year  = {2023},

date = {2023-02-01},

journal = {Clin Psychol Rev},

volume = {99},

pages = {102233},

abstract = {This systematic review and meta-analysis aims to synthesize the efficacy of culturally sensitive prevention programs for substance use outcomes among U.S. adolescents of color (aged 11 to 18 years old) and explore whether the intervention effects vary by participant and intervention characteristics. Eight electronic databases and grey literature were searched for eligible randomized controlled trials through September 2022. Robust variance estimation in meta-regression was used to synthesize treatment effect size estimates and to conduct moderator analysis. After screening, 30 unique studies were included. The average treatment effect size across all substance use outcomes (including 221 effect sizes) was Hedges's g = -0.20, 95% CI = [-0.24, -0.16]. The synthesized effect sizes were statistically significant across types of substances (alcohol, cigarette, marijuana, illicit and other drugs, and unspecified substance use), racial/ethnic groups (Hispanic, Black, and Native American), and different follow-ups (0-12 months, >12 months). Very few studies reported substance use consequences as outcomes and the synthesized effect size was non-significant. Meta-regression findings suggest that the intervention effects may vary based on the type of substance. This meta-analysis found supportive evidence of culturally sensitive prevention programs' efficacy in preventing or reducing substance use among Black, Hispanic, and Native American adolescents. More substance use prevention efforts and evidence is needed for Asian American, Pacific Islander, and multiracial adolescents.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36780161,

title = {Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial},

author = {C Austin Zamarripa and Tory R Spindle and Renuka Surujunarain and Elise M Weerts and Sumit Bansal and Jashvant D Unadkat and Mary F Paine and Ryan Vandrey},

doi = {10.1001/jamanetworkopen.2022.54752},

issn = {2574-3805},

year  = {2023},

date = {2023-02-01},

journal = {JAMA Netw Open},

volume = {6},

number = {2},

pages = {e2254752},

abstract = {IMPORTANCE: Controlled clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of Δ9-tetrahydrocannabinol (Δ9-THC). No studies have evaluated differences in pharmacokinetics (PK) of Δ9-THC and pharmacodynamics (PD) between orally administered cannabis extracts that vary with respect to Δ9-THC and CBD concentrations.nnOBJECTIVE: To compare the PK and PD of orally administered Δ9-THC-dominant and CBD-dominant cannabis extracts that contained the same Δ9-THC dose (20 mg).nnDESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a within-participant, double-blind, crossover study conducted from January 2021 to March 2022 at the Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, MD. Eighteen healthy adults completed 3 randomized outpatient experimental test sessions that were each separated by at least 1 week.nnINTERVENTIONS: Brownies containing (1) no cannabis extract (ie, placebo); (2) Δ9-THC-dominant extract (20 mg Δ9-THC with no CBD); and (3) CBD-dominant extract (20 mg Δ9-THC + 640 mg CBD) were administered to participants 30 minutes prior to administering a cytochrome P450 (CYP) probe drug cocktail, which consisted of 100 mg caffeine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan, and 2 mg midazolam.nnMAIN OUTCOMES AND MEASURES: Change-from-baseline plasma concentrations for Δ9-THC or Δ9-THC metabolites and scores for subjective drug effects, cognitive and psychomotor performance, and vital signs. The area under the plasma vs concentration vs time curve (AUC) and maximum plasma concentration (Cmax) were determined.nnRESULTS: The participant cohort of 18 adults included 11 males (61.1%) and 7 females (38.9%) with a mean (SD) age of 30 (7) years who had not used cannabis for at least 30 days prior to initiation of the study (mean [SD] day since last cannabis use, 86 [66] days). The CYP cocktail + placebo brownie and the CYP cocktail did not affect any PD assessments. Relative to CYP cocktail + Δ9-THC, CYP cocktail + Δ9-THC + CBD produced a higher Cmax and area under the plasma concentration vs time curve for Δ9-THC, 11-OH-Δ9-THC, and Δ9-THC-COOH. The CYP cocktail + Δ9-THC + CBD increased self-reported anxiety, sedation, and memory difficulty, increased heart rate, and produced a more pronounced impairment of cognitive and psychomotor performance compared with both CYP cocktail + Δ9-THC and CYP cocktail + placebo.nnCONCLUSIONS AND RELEVANCE: In this randomized clinical trial of oral Δ9-THC and CBD, stronger adverse effects were elicited from a CBD-dominant cannabis extract compared with a Δ9-THC-dominant cannabis extract at the same Δ9-THC dose, which contradicts common claims that CBD attenuates the adverse effects of Δ9-THC. CBD inhibition of Δ9-THC and 11-OH-Δ9-THC metabolism is the likely mechanism for the differences observed. An improved understanding of cannabinoid-cannabinoid and cannabinoid-drug interactions are needed to inform clinical and regulatory decision-making regarding the therapeutic and nontherapeutic use of cannabis products.nnTRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT04201197.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35266779d,

title = {A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal},

author = {Cecilia L Bergeria and Hongjun Tan and Denis Antoine and Elise M Weerts and Andrew S Huhn and J Gregory Hobelmann and Kelly E Dunn},

doi = {10.1037/pha0000550},

issn = {1936-2293},

year  = {2023},

date = {2023-02-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {1},

pages = {194--203},

abstract = {Successful management of opioid withdrawal improves long-term treatment outcomes and reduces opioid use-related morbidity and mortality. Mechanistically supported pharmacotherapeutic approaches are needed to effectively manage acute and protracted opioid withdrawal. Buspirone is a D2 antagonist and 5-HT1a agonist that may decrease opioid withdrawal. Individuals ( = 15) admitted to a residential treatment center for opioid use disorder (OUD) were enrolled into a double-blind randomized clinical trial to assess the efficacy and acceptability of buspirone (45 mg/day) as an adjunctive medication to buprenorphine-assisted, supervised opioid withdrawal. Participants completed daily questionnaires which consisted of the Subjective Opiate Withdrawal Scale (SOWS) and a consensus sleep diary, which assessed total sleep time, time to sleep onset, and sleep quality. Total SOWS scores, individual opioid withdrawal symptoms and sleep outcomes were assessed between treatment groups (Placebo and Buspirone) and over time in a repeated measures linear mixed model. Total SOWS scores significantly decreased across study phases for both groups but decreased to a greater extent among individuals assigned to buspirone during both the first and second week of stable buspirone. Greater decreases in withdrawal were observed during Week 2 of stable buspirone relative to Week 1 of stable buspirone. Participants also reported significant increases in sleep duration and significant decreases in latency to sleep onset. This study provides further support that buspirone can help mitigate opioid withdrawal during a supervised opioid taper. Buspirone may confer unique benefits during protracted withdrawal periods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35266780d,

title = {Can initial experiences with drugs predict future drug abuse risks?},

author = {Neil B Varshneya and Kelly E Dunn and Caitlyn J Grubb and Sandra I Okobi and Andrew S Huhn and Cecilia L Bergeria},

doi = {10.1037/pha0000559},

issn = {1936-2293},

year  = {2023},

date = {2023-02-01},

journal = {Exp Clin Psychopharmacol},

volume = {31},

number = {1},

pages = {186--193},

abstract = {Initial experiences with drugs may influence an individual's motivations for continued use. This study evaluated the relationship between subjective effects elicited by an individual's first use of alcohol or cannabis, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) alcohol use disorder (AUD) or cannabis use disorder (CUD) severity, and behavioral economic demand for alcohol or cannabis. Self-reports of initial subjective effects associated with drugs were analyzed for  = 463 participants whose first substance use was either alcohol or cannabis. The likelihood that a particular subjective effect at the time of first use was associated with current AUD/CUD was assessed using ordinal logistic regression with subjective effects as predictors of DSM-5 severity. Behavioral economic demand was assessed using a hypothetical purchase task in which participants indicated their hypothetical consumption of alcohol or cannabis as a function of price. Significant associations were observed for initial subjective effects elicited by alcohol or cannabis and increased DSM-5 severity: (alcohol) relief (OR = 2.52 [95% CI 1.51-4.25],  = .0005) and (cannabis) energetic (OR = 2.31 [95% CI 3.27-55.5],  = .0004). The mean (± SEM)  value for the alcohol subgroup endorsing relief ($96.22 ± $26.48) was significantly greater than the  value for the alcohol subgroup not endorsing relief ($33.81 ± $12.93), (237) = 2.276,  = .0237. These results suggest that the initial subjective effects associated with a given substance may predict the development and/or severity of substance misuse and substance use disorders (SUDs). These findings are consistent with anecdotal reports that persons with SUD feel energized by the use of substances whereas persons without SUD do not report experiencing such subjective effects upon first use. (PsycInfo Database Record (c) 2023 APA, all rights reserved).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}